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SUMMARY 
 
Tenascin-C (TNC) is involved in tumor initiation and metastasis, and high 
TNC expression has been associated with poor prognosis in cancers such as 
glioma, breast, colon and lung carcinoma (Orend and Chiquet-Ehrismann, 
2006; Oskarsson, 2013). Previous studies have shown that the transcriptional 
regulator megakaryoblastic leukemia-1 (MKL1) induces TNC expression in 
both normal and transformed mammary epithelial cells, and that this induction 
requires the potential DNA-binding SAP domain of MKL1 (Asparuhova et al., 
2011). Therefore, we postulated that SAP-dependent MKL1 action might be 
responsible for the tumor-specific induction of TNC. By transcript profiling 
analyses, we identified genes that are co-regulated with TNC in HC11 mouse 
mammary epithelial cells. We found that the expression of this gene set is 
associated with high-proliferative poor-outcome classes in human breast 
cancer and with reduced survival rate for breast cancer patients independent 
of tumor grade. Many of the newly discovered SAP-dependent/SRF-
independent MKL1 target genes are strongly implicated in cell proliferation, 
cell motility and cancer. Indeed, downregulation of these transcripts by 
overexpression of MKL1 lacking the SAP domain inhibited cell growth as well 
as cell migration. Interestingly, many of the SAP-dependent MKL1 target 
genes, including WNT1 inducible signaling pathway protein 1 (WISP1/CCN4) 
that we studied further, were mechanoresponsive (Gurbuz et al., 2014).   
 
WISP1 is a secreted, matricellular protein assigned to the CCN family, and 
aberrant WISP1 expression is observed in various pathologies including 
fibrosis and cancer (Berschneider et al., 2011). However, relatively little is 
known about the mechanistic details of its function. In our studies, we found 
that endogenous WISP1 expression correlates with the metastatic potential of 
isogenic mouse breast cancer cell lines. Furthermore, we observed that 
WISP1 mRNA levels within the mouse mammary gland tissue significantly 
increased upon irradiation, a treatment known to induce modifications in the 
tumor microenvironment leading to increased metastasis (Ruegg et al., 2011). 
Finally, we produced recombinant WISP1 protein and confirmed that WISP1 
is N-glycosylated and that the secreted form of the protein undergoes 
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additional post-translational modifications that increase its size and possibly 
add functional diversity to the protein. Using our purified recombinant protein 
we generated specific anti-WISP1 antibodies. In the future, these antibodies 
can be used to detect WISP1 in various tumor tissues.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Signaling in Cancer: From Extracellular Space to Nucleus 
 
1.1.1 The Extracellular Matrix  
The extracellular matrix (ECM) is a non-cellular structure and is present in all 
tissues and organs. It not only passively provides physical support for tissues, 
organs and individual cells, but also actively modulates cellular responses, 
such as cell migration, proliferation, differentiation and survival through 
biochemical and biomechanical cues (Frantz et al., 2010; Mouw et al., 2014). 
ECM binds to soluble growth factors to control their localization, function and 
presentation to cells, and provides binding sites for cell-surface receptors, 
such as integrins and syndecans (Harburger and Calderwood 2009; Hynes, 
2009; Rozario and DeSimone 2010). Through cell surface receptors, ECM is 
involved in the transmission of extracellular signals and in the regulation of 
gene transcription. 
 
ECM is composed of proteoglycans (e.g., perlecan and decorin) and 
glycoproteins (e.g., collagens and non-collagenous proteins, including 
tenascins, laminins and fibronectin) (Frantz et al. 2010; Rozario and 
DeSimone 2010; Mouw et al., 2014). ECM proteins share common structural 
motifs, such as the Arg-Gly-Asp (RGD) sequence that is involved in the 
recognition and binding to cell surface receptors of the integrin family (Hynes, 
2009; Rozario and DeSimone 2010). Collagen is the most abundant protein 
within the ECM and makes up 30% of the total protein mass of a multicellular 
animal (Frantz et al. 2010; Rozario and DeSimone 2010; Mouw et al., 2014). 
Another fibrous glycoprotein within the ECM is fibronectin (FN). FN is 
secreted as a soluble dimer and then assembled into insoluble elastic fibrils 
by cells. The fibrillar fibronectin is biologically active and is involved in cellular 
processes such as adhesion, migration, proliferation, and differentiation, as 
well as in development, wound healing and metastasis of tumor cells (Baneyx 
et al., 2002). Likewise, a structurally related ECM glycoprotein family, the 
tenascins can modulate cellular behavior such as cell migration during wound 
healing and tissue development (Tucker and Chiquet-Ehrismann, 2009).  
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The composition of the ECM varies among tissues or physiological states, 
such as normal versus cancer (Frantz et al., 2010; Mouw et al., 2014). Similar 
to soluble growth factors, the molecular composition and the physical 
properties of the matrix (e.g., stiffness, elasticity) can influence cell behavior 
and cell fate (Rozario and DeSimone 2010). The rigidity or compliance of the 
ECM plays an important role in the differentiation and organization of various 
tissues and organs. When mesenchymal stem cells were plated on collagen-
coated acrylamide gels that possess the elasticity of brain, muscle or bone 
tissues they gave rise to neurogenic, myogenic and osteogenic cell fates, 
respectively (Engler et al., 2006). In the case of normal mammary epithelial 
cells, when cultured on a flexible ECM, such as a floating 3D collagen gel, 
they differentiate into tubules (Wozniak et al., 2003). On the other hand, when 
encountering a stiff ECM with high collagen concentration mammary epithelial 
cells obtain an undifferentiated, proliferative, and malignant phenotype 
(Wozniak et al., 2003; Paszek et al., 2005).  
 
In addition, ECM is dynamically remodeled, and its molecular components are 
subjected to post-translational modifications that influence its tensile strength 
and elasticity (Butcher et al., 2009; Frantz et al., 2010). To maintain tissue 
homeostasis, ECM composition and remodeling are tightly controlled by 
secretion of various ECM proteins, enzymes and growth factors.  FN, 
tenascins, collagens, proteoglycans, metalloproteinases (MMPs), tissue 
inhibitors of MMPs, lysyl oxidase (LOX) that crosslinks and stiffens the ECM, 
and transforming growth factor-β (TGF-β) which induces ECM gene 
transcription are crucial players in this regulatory process (Butcher et al., 
2009; Hynes, 2009; Frantz et al., 2010; Mouw et al., 2014). Deregulation of 
the matrix remodeling circuit may alter ECM composition and organization, 
and promote diseases including solid tumors (Figure 1), the hardening of 
arterial walls, atherosclerosis, and fibrosis (Lessey et al., 2012). For instance, 
as a result of increased collagen production as well as crosslinking in the 
stroma, tumors are stiffer than the surrounding healthy tissue and cancers are 
often diagnosed by a change of tissue rigidity sensed by palpation (Huang 
and Ingber, 2005; Butcher et al., 2009; Levental et al., 2009). Furthermore, 
women with mammographically dense breast tissue (high relative ratio of 
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ECM collagen to adipose cell volume ratio) have a four- to six-fold increased 
risk of developing breast cancer, and stiff crosslinked collagen was shown to 
be a poor prognosis factor in breast cancer (Boyd et al., 1998; Boyd et al., 
2011; Conklin et al., 2011).  
 
 
Figure 1: Increased extracellular matrix (ECM) stiffness compromises mechanoreciprocity 
and contributes to tumor progression in mammary tissue. Transformed epithelial cells secrete 
soluble factors that activate stromal cells and stimulate ECM remodeling and tissue stiffening. 
The activated stroma leads to increased survival and proliferation of tumor cells, and 
stimulate immune cell infiltration. The expanding tumor mass exerts outward projecting 
compression forces on the basement membrane. ECM balances these forces by an inward 
projecting resistance force. The modified tensional homeostasis facilitates tumor migration 
and invasion. (Adapted from Butcher et al., 2009).  
	
  
1.1.2 Mechanotransduction through Rho GTPase signaling and its role 
in tumor progression 
Rho family small GTPases, such as Rho, Rac, and Cdc42, are involved in 
multiple cellular events, including cell contraction and actin cytoskeleton 
organization, microtubule dynamics, cell polarity, cell migration, neurite 
outgrowth and cytokinesis (Amano et al., 2010). All members of the family 
have distinct roles in cytoskeletal organization. Rho regulates stress fiber 
formation and cell contraction; Rac and Cdc42 regulate the formation of 
lamellipodia and filopodia, respectively, and promote the formation of cell 
protrusions (Hall, 2005).  
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Under normal physiological conditions all cells are exposed to different types 
of mechanical forces and adapt to these forces by changing their cytoskeletal 
organization and by remodeling the microenvironment to re-establish the force 
equilibrium (Butcher et al., 2009; Lessey et al., 2012). The forces acting on 
cells can be cyclic, such as the blood flow, heartbeat or breathing, whereas 
others are sustained for varying periods of time (Butcher et al., 2009; Lessey 
et al., 2012). Endothelial cells and vascular smooth muscle cells lining blood 
vessels experience parallel forces, pulsatile stretching and shear forces 
during blood flow (Lessey et al., 2012; Burridge and Wittchen, 2013). Cells in 
the skeletal system (e.g. bones, joints, cartilage, ligaments) are exposed to 
perpendicular compression force (Lessey et al., 2012). Cells are able to sense 
these physical cues and translate them into biochemical signals, a 
phenomenon called cellular mechanotransduction. Mechanical signals are 
perceived and transmitted to the actin cytoskeleton through cell surface 
receptors of the integrin family that act as mechanoreceptors (Ridley and Hall, 
1992; Wang et al., 1993; Chrzanowska-Wodnicka and Burridge, 1996). 
Mechanotransduction provides a finely regulated feedback circuit and enables 
a reciprocal interaction between the cells and their microenvironment.   
 
To balance internal and external forces and to maintain tissue homeostasis, 
cells evaluate the exogenous mechanical signals within the tissue 
microenvironment and generate an endogenous tension. Multiple signaling 
pathways are involved in the integration of mechanical signals and generation 
of the reciprocal force response, and many of them converge in the activation 
of the small GTPase Rho (Lessey et al., 2012). Rho is responsible for the 
tension that is generated within the cells (Chrzanowska-Wodnicka and 
Burridge, 1996). Activation of Rho stimulates myosin contractility and results 
in actin stress fiber assembly (Ridley and Hall, 1992). Stress fibers consist of 
actin filaments, myosin II, and many other proteins, and are force-generating 
and tension-bearing structures (Burridge and Wittchen, 2013). Several 
downstream effector molecules of Rho, including the Rho-associated kinase 
(Rho-kinase/ROCK/ROK) and mDia are involved in these responses (Amano 
et al., 2010). ROCK and mDia act concurrently to facilitate actin stress fiber 
formation (Watanabe et al., 1999). The ratio of these two effector proteins is 
	
   7	
  
reflected in the pattern of stress fibers; ROCK activity is associated with large 
condensed stress fibers, whereas mDia activity induces the assembly of 
filamentous F-actin (Watanabe et al., 1999). Once Rho is activated, it 
interacts with ROCK and activates it (Amano et al., 1996). The activated 
ROCK regulates myosin light chain (MLC) activity either directly by 
phosphorylation of the protein (Amano et al., 1996) or indirectly by 
phosphorylation and consequent inhibition of the MLC phosphatase (Kimura 
et al., 1996). The activation of MLC promotes assembly of myosin II, and 
generates a contractile force on actin filaments, which consequently results in 
the formation of stress fibers and focal adhesions (Figure 2) (Amano et al., 
1996; Lessey et al., 2012; Burridge and Wittchen, 2013). Another downstream 
effector of Rho, focal adhesion kinase (FAK) is a non-receptor protein tyrosine 
kinase localized at focal adhesions and is involved in converting external 
mechanical input into chemical signals (Wang et al., 2001b). Upon 
phosphorylation at its autophosphorylation site, Y397, FAK is activated and 
localizes to focal adhesions, which occurs in a Rho-dependent manner (Clark 
et al., 1998). FAK and its associated signaling pathways act as mediators of 
cell cycle regulation (Zhao et al., 1998). Furthermore, FAK promotes cell 
motility, survival and proliferation, and drives tumor progression and 
metastasis (Sulzmaier et al., 2014). 
 
 
 
 
Figure 2: Rho GTPase signaling. Activated 
Rho mediates the formation of actin stress 
fibers through its downstream effector 
proteins ROCK (Rho-associated kinase) 
and mDia. ROCK regulates myosin light 
chain (MLC) activity either directly by 
activation of the protein or indirectly by 
inhibition of the MLC phosphatase. 
Activated MLC promotes assembly of 
myosin II with actin filaments and formation 
of actin stress fibers. mDia induces actin 
polymerization and formation of thin actin 
filaments. (Adapted from Lessey et al., 
2012). 
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An injury or chronic inflammation may increase matrix stiffness and 
compromise the “mechanoreciprocity” between the cells and the ECM 
resulting in a sustained cytoskeletal tension, which in turn promotes the 
malignant transformation of a tissue (Paszek et al., 2005; Butcher et al., 
2009). Matrix rigidity can expand flexible ECM proteins and uncover cryptic 
binding sites within them (Hynes, 2009). As a conseqeunce, the extended 
ECM proteins can bind to additional growth factors and receptors, which in 
turn enhances integrin expression (Yeung et al., 2005) and clustering, 
Rho/ROCK mediated cytoskeletal contractility, and subsequent focal adhesion 
and actin stress fiber formation at the cell-ECM contact sites. (Ridley and Hall, 
1992; Chrzanowska-Wodnicka and Burridge, 1996; Bershadsky et al., 2003; 
Wozniak et al., 2003; Paszek et al., 2005; Vogel, 2006). The final response is 
increased FAK phosphorylation and cell proliferation (Wozniak et al., 2003). 
 
When cells are grown on a stiff matrix they exhibit elevated Rho activity, 
increased number of focal adhesions, and higher tension compared to cells 
grown on a compliant ECM (Paszek et al., 2005). Rho stimulates cell cycle 
progression, increases cell proliferation, disrupts cell-cell junctions and 
cellular organization, and finally results in a “dedifferentiation phenotype” 
(Ridley and Hall, 1992; Chrzanowska-Wodnicka and Burridge, 1996; Paszek 
et al., 2005). Thus, activated Rho signaling through matrix stiffening facilitates 
tumor progression (Wozniak et al., 2003; Huang and Ingber, 2005; Paszek et 
al., 2005). On the contrary, a flexible matrix results in the downregulation of 
Rho and FAK activity, and subseqeunt differentiation of cells (Wozniak et al., 
2003).  
 
Similar to mechanical forces exerted exogenously on cells, it was shown that 
endogenous forces generated within the cells might activate 
mechanotransduction pathways and promote tumor growth and progression 
(Samuel et al., 2011). Conditional activation of ROCK in mouse skin results in 
generation of actomyosin contractile tension within the cell, which 
consequently elevates collagen deposition, increases tissue stiffness, and 
promotes β-catenin-mediated proliferation (Samuel et al., 2011). This study 
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underlines how an intermediate player of Rho GTPase signaling affects tissue 
homeostasis and tumor development (Samuel et al., 2011). 
 
Rho GTPase signaling not only plays a role in cell proliferation and survival, 
but also in cell motility. The motility of eukaryotic cells is driven by the 
assembly and disassembly of actin filaments (Pollard and Borisy, 2003). Actin 
cytoskeleton reorganization enables cells to migrate in response to 
extracellular stimuli, and is required for the proper formation of organs and 
tissues during embryonic development (Olson and Sahai, 2009). In 
pathological situations like cancer, mechanical tension alters the 
mechanotransduction pathways and enhances the invasive behavior of tumor 
cells (Olson and Sahai, 2009).  
 
Cells can move in different ways. They either migrate individually 
(mesenchymal and amoeboid/ rounded) or collectively as multicellular units 
maintaining their cell-cell contacts (Friedl and Wolf, 2009). The two distinct 
single-cell migration behaviors, mesenchymal and amoeboid are associated 
with different effectors of Rho GTPase signaling (Sahai and Marshall, 2003). 
Elevated Rho/ ROCK activity and consequent actomyosin contractile tension, 
as well as inhibition of matrix degrading enzymes induces amoeboid-like 
migration that is associated with invasion and metastasis (Sahai and Marshall, 
2003; Friedl and Wolf, 2009). In contrast, low Rho activity is associated with 
amoeboid-to-mesenchymal transition (Friedl and Wolf, 2009). For instance, 
Sahai et al. showed that Smurf1 E3 ubiquitin ligase, which targets Rho for 
degradation is an important regulator of tumor cell migration (Sahai et al., 
2007). Inhibition of Smurf1 leads to increased Rho activity changing the tumor 
cell morphology from mesenchymal to amoeboid and enhancing invasion into 
blood vessels (Sahai et al., 2007).  
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1.1.3 Megakaryoblastic leukemia protein 1 (MKL1): A link between the 
ECM and the nucleus 
Megakaryoblastic leukemia protein 1 (MKL1), also known as megakaryocytic 
acute leukemia (MAL), myocardin-related transcription factor-A (MRTF-A) or 
basic SAP and coiled-coil (BSAC), belongs to the MRTF family and functions 
as a co-activator for serum response factor (SRF) to enhance SRF-dependent 
transcription (Wang et al., 2002; Scharenberg et al., 2010). SRF activates the 
expression of genes with CArG box-containing promoters and regulates 
several important biological processes including gastrulation and 
development, as well as actin cytoskeletal dynamics, survival and apoptosis 
at the cellular level (Olson and Nordheim, 2010).  
 
MKL1 is expressed in a wide range of embryonic and adult tissues, with the 
most abundant expression in heart and liver (Wang et al., 2002). MKL1 
knockout mice are viable, but females are unable to feed their offspring due to 
impaired mammary myoepithelial cell differentiation (Li et al., 2006; Sun et al., 
2006). MKL1 was originally identified as a genomic fusion partner of RNA-
binding motif protein 15 (RBM15), also known as OTT, in infant acute 
megakaryoblastic leukemia (AMKL), caused by chromosomal translocation 
t(1;22) (p13;q13) (Ma et al., 2001; Mercher et al., 2001). In addition to the 
involvement in AMKL, MKL1 has been implicated in actin-based cell 
adhesion, spreading, migration and invasion in vitro as well as in the 
colonization of tumor cells in an in vivo experimental metastasis assay 
(Medjkane et al., 2009). In support of the role of MKL1 in tumor progression, it 
was shown that suppressor of cancer cell invasion (SCAI), a negative 
regulator of invasive cell migration, binds to MKL1 and inhibits its 
transcriptional activity by forming a ternary complex with SRF (Brandt et al., 
2009). Furthermore, MKL1 is involved in TGF-β-induced EMT via an 
interaction with Smad3 transcription factor (Morita et al., 2007). The MKL1-
Smad3 complex has been reported to drive the expression of the slug gene, 
thereby inducing the dissociation of cell-cell contacts (Morita et al., 2007). 
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MKL1 shares common homology domains with other MRTF family members 
(Figure 3), including three highly conserved N-terminal Arg-Pro-X-X-X-Glu-
Leu (RPEL) motifs, basic domains 1 and 2 (B1 and B2), glutamine-rich region 
(Q), SAP domain, leucine zipper-like region (LZ), and a C-terminal 
transactivation domain (TAD) (Scharenberg et al., 2010). MKL1 associates 
with SRF through its B1 domain and the adjacent Q domain; the RPEL 
domain mediates the interaction of MKL1 with globular actin (G-actin); basic 
regions, B1 and B2 are required for nuclear localization of MKL1 (Olson and 
Nordheim, 2010). Moreover, MKL1 contains a SAP domain, named after SAF-
A/B, acinus and PIAS, a peptide motif found in several proteins known to 
contact DNA (Aravind and Koonin, 2000; Olson and Nordheim, 2010). 
Mutations in the SAP domain are shown to disrupt the ability of myocardin to 
activate a subset of SRF-dependent genes (Wang et al., 2001a), however 
deletion of this region had no obvious effect on the transcriptional activity of 
MKL1 and MKL1-SRF complex formation (Cen et al., 2003; Miralles et al., 
2003). The LZ domain is involved in homo- and heterodimerization of 
myocardin and MKLs (Olson and Nordheim, 2010). The transcriptional 
activation domain, TAD is located at the C-terminal end of MKL1, and is 
required for the stimulation of SRF activity (Olson and Nordheim, 2010). 
 
Figure 3: Structure of myocardin-related transcription factor (MRTF) family members. Functional 
homology domains are indicated. Abbreviations: RPEL: actin-binding motifs with Arg-Pro-X-X-X-Glu-
Leu core consensus; B1 and B2: basic domains; Q: glutamine-rich domain; SAP: homology domain 
found in SAF-A/B, acinus, PIAS; LZ: leucine-zipper-like domain; TAD: transactivation domain. A 
cardiac-specific splice variant of myocardin (top row) contains a unique N-terminal sequence that is 
involved in the interaction with myocyte-specific enhancer factor 2 (MEF2) transcription factor, a 
MADS-box transcription factor related to serum response factor (SRF) (indicated by an arrow). This 
domain is present also in another member of MRTF family, MEF2-activating SAP transcriptional 
regulator (MASTR). MASTR lacks the basic domains and the glutamine-rich domain, which are 
involved in SRF interaction. The RBM15-MKL1 fusion protein observed in acute megakaryoblastic 
leukemia (AMKL) is shown at the bottom row. (Adapted from Olson and Nordheim, 2010).  
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The subcellular localization and following transcriptional activity of MKL1 is 
regulated by Rho GTPase signaling that transmits physical or biochemical 
extracellular signals to the actin cytoskeleton (Figure 4) (Butcher et al., 2009; 
Scharenberg et al., 2010). In unstimulated cells, MKL1 is sequestered in the 
cytoplasm by forming a stable complex with monomeric G-actin through its N-
terminal RPEL motifs, but translocates into the nucleus upon serum-induced 
Rho GTPase pathway activation and subsequent F-actin formation (Ridley 
and Hall, 1992; Miralles et al., 2003; Olson and Nordheim, 2010). Nuclear G-
actin also regulates the subcellular localization and the transcriptional activity 
of MKL1. Nuclear G-actin was shown to facilitate nuclear export of MKL1 and 
to prevent nuclear MKL1 from activating SRF target genes, unless actin 
binding is disrupted (Vartiainen et al., 2007). Thus, cellular G-actin regulates 
MKL1 at three levels: nuclear import, nuclear export and nuclear activation or 
inactivation of MKL1-SRF-dependent transcription (Vartiainen et al., 2007).  
 
Every stimulus that activates Rho GTPase signaling, including mechanical 
force, triggers the nuclear accumulation and consequent transcriptional 
activity of MKL1. Not surprisingly, it was observed that MKL1 translocates 
from the cytoplasm to the nucleus when strain is applied to rat cardiac 
fibroblasts (Zhao et al., 2007) and to mouse embryonic fibroblasts (Maier et 
al., 2008) in vitro or in mechanically overloaded rat bladders in vivo (Hanna et 
al., 2009). Additionally, mechanical strain-induced expression of the ECM 
protein tenascin-C (TNC) depends on Rho GTPase/ actin signaling pathway 
(Chiquet et al., 2004; Sarasa-Renedo et al., 2006; Maier et al., 2008). 
Previous work from our group revealed that MKL1 regulates the mechanical 
strain-induced TNC expression in mouse fibroblasts as well as in normal and 
transformed mouse mammary epithelial cells (Asparuhova et al., 2011). TNC 
induction by MKL1 required the SAP domain of MKL1, but was independent of 
SRF interaction, demonstrating for the first time the role of MKL1 as a bona 
fide transcription factor (Asparuhova et al., 2011).  
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Figure 4: Megakaryoblastic leukemia protein 1 (MKL1) is a mediator of Rho GTPase/ actin 
signaling pathway and links the extracellular matrix to the nucleus. The subcellular 
localization and following transcriptional activity of MKL1 is regulated through its interaction 
with G-actin. Extracellular stimuli (e.g. lysophosphatidic acid (LPA), serum, transforming 
growth factor-β (TGF-β)) can activate Rho signaling. Activated Rho induces actin 
polymerization and results in the nuclear translocation of MKL1. MKL1 acts as transcriptional 
co-activator of serum response factor (SRF) and is involved in the regulation of cytoskeletal 
dynamics. Furthermore, MKL1 plays a role in epithelial to mesenchymal transition via an 
interaction with Smad3 transcription factor. In addition to its transcriptional coactivator 
function of SRF and Smad3, previous studies from our group revealed that MKL1 may act as 
a bona fide transcription factor mediating SRF-independent induction of tenascin-C (TNC) 
transcription (Asparuhova et al., 2011). (Adapted from Cen et al., 2004; Morita et al., 2007).  
 
 
1.1.4 The role of the tumor stroma in cancer 
In 1889, the English surgeon Stephen Paget proposed the “seed and soil” 
hypothesis to explain why disseminating tumor cells tend to metastasize to 
specific organs, independently of the vascular anatomy and the rate of blood 
flow (Paget, 1889). Paget compared the cells of the primary tumor to the 
seeds of a plant, and the affected organs to the soil, which provides the fertile 
environment for the metastatic tumor growth.  
 
Today it has been widely accepted that cancer and metastasis are not only a 
result of genetic alterations or dysregulation of signaling pathways within the 
tumor cells, but also products of the reciprocal interaction between the tumor 
cells and the surrounding tumor stroma through cell-cell contacts and 
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paracrine signals (Figure 5) (Fidler, 2003; Mueller and Fusenig, 2004; Huang 
and Ingber, 2005; De Wever et al., 2008). The tumor stroma consists of 
fibroblasts, endothelial cells, pericytes, inflammatory cells, immunocytes, 
macrophages, and adipocytes, and provides the connective-tissue framework 
of the tumor (cf. Figure 1; Mueller and Fusenig, 2004; Kalluri and Zeisberg, 
2006; De Wever et al., 2008; Joyce and Pollard, 2009; Psaila and Lyden, 
2009). Malignant cells interact with their “niche”, the specialized local tissue 
microenvironment that supports tumor maintenance and growth at the primary 
tumor and at secondary metastatic sites (Psaila and Lyden, 2009). 
 
Cancer cells secrete growth factors, including fibroblast growth factor (FGF), 
vascular endothelial growth factor (VEGF), platelet-derived growth factor, 
interleukins, colony-stimulating factors, and TGF-β, thus activate the stromal 
cells (Mueller and Fusenig, 2004; Joyce and Pollard, 2009). As a result, the 
“reactive tumor stroma”, also known as desmoplasia supports the tumor 
progression through the stimulation of cancer-cell survival, proliferation, 
migration and invasion, as well as the activation of angiogenesis and the 
inflammatory response (Fidler, 2003; Mueller and Fusenig, 2004; Joyce and 
Pollard, 2009). Moreover, the tumor cells can modulate the ECM to support 
their growth at the metastatic niche by secreting TNC (Oskarsson et al., 2011) 
and LOX (Erler et al., 2009).  
 
Reactive tumor stroma harbors different activated cell types including 
carcinoma-associated fibroblasts (CAFs) (Kalluri and Zeisberg, 2006; De 
Wever et al., 2008). CAFs are mesenchymal cells that express different 
markers, such as α-smooth-muscle actin, vimentin, desmin and fibroblast 
activation protein (Mueller and Fusenig, 2004; Kalluri and Zeisberg, 2006). 
Like tumor cells, CAFs can change the composition of the ECM and promote 
tumor progression as well as metastasis by secreting ECM proteins including 
collagens, SPARC (secreted protein acidic and rich in cysteine also known as 
osteonectin), FN, periostin and tenascins (Kalluri and Zeisberg, 2006; 
Malanchi et al., 2012; Oskarson and Massague, 2012; Junttila and Sauvage, 
2013; Oskarsson, 2013). Furthermore, CAFs secrete MMPs, which are 
involved in ECM degradation and remodeling, as well as growth factors and 
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cytokines such as insulin-like growth factor 1, hepatocyte growth factor, 
VEGF, stromal-cell-derived factor 1 and TGF-β, which promote endothelial 
cell proliferation and angiogenesis, tumor-cell survival, migration and invasion 
(Li et al., 2003; De Wever et al., 2004; Mueller and Fusenig, 2004; Sato et al., 
2004; Kalluri and Zeisberg, 2006; Joyce and Pollard, 2009; Junttila and 
Sauvage, 2013). Through the secretion of inflammatory cytokines CAFs 
induce an immune response within the tumor stroma. The paracrine 
interaction between the inflammatory cells and tumor cells involving the 
secretion of colony-stimulating factor 1 (CSF1), epidermal growth factor and 
their receptors, induces the migration of cancer cells towards perivascular 
macrophages and the consequent intravasation into the blood circulation 
(Joyce and Pollard, 2009). 
 
 
 
Figure 5: Reciprocal interactions within the tumor stroma contribute to tumor progression. 
Cancer cells modulate their microenvironment and activate the stroma through a variety of 
stroma-modulating proteins, including extracellular matrix (ECM) protein Tenascin-C (TNC), 
lysyl oxidase (LOX), metalloproteinases (MMPs), fibroblast growth factor (FGF), members of 
the vascular endothelial growth factor (VEGF) family, platelet-derived growth factor (PDGF), 
colony-stimulating factors (CSFs), and transforming growth factor-β (TGF-β). (Factors 
secreted by the tumor cells are indicated in red). Activated fibroblasts within the tumor 
stroma, carcinoma-associated fibroblasts (CAFs) communicate with cancer cells, endothelial 
cells, pericytes and inflammatory cells through secretion of ECM proteins (collagens, SPARC 
(secreted protein acidic and rich in cysteine), fibronectin that contains the extra domain a 
(EDA-fibronectin), periostin and TNC), growth factors (VEGF, insulin-like growth factor 1 
(IGF1), hepatocyte growth factor (HGF), TGF-β and stromal-cell-derived factor 1 (SDF1)), 
inflammatory cytokines (monocyte chemotactic protein 1 (MCP1) and interleukin 1 (IL-1)), and 
MMPs. (Factors provided to tumor cells are indicated in black). In addition to CAFs, pericytes 
provide SDF1 to tumor cells to stimulate cancer-cell proliferation, migration and invasion. 
EGF: epithelial growth factor. (Adapted from Kalluri and Zeisberg, 2006).  
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The tumor microenvironment might serve as a potential therapeutic target. 
Combinatorial use of chemotoxic therapies with drugs that target the activated 
stroma might increase the efficiency of cancer treatment. Modulating tumor 
cell-stroma interaction through the inhibition of ECM receptors or by 
neutralizing paracrine growth factor and inflammatory cytokine signaling can 
reverse the malignant phenotype (Mueller and Fusenig, 2004; Junttila and 
Sauvage, 2013). For instance, in a breast cancer model, treatment of tumor 
cells with β1-integrin blocking antibody led to a morphological and functional 
reversion to a normal phenotype, and when these cells were injected into 
nude mice they had reduced number and size of tumors (Weaver et al., 
1997). Furthermore, non-steroidal anti-inflammatory drugs have been used to 
inhibit the inflammatory cells and cytokines, and they have been shown to be 
an effective treatment regimen for colorectal cancer (Ricchi et al., 2003). On 
the other hand, MMP inhibitors, including tanomastat, marimastat and 
prinomastat, which were designed to maintain the ECM integrity were not 
beneficial over the standard-of-care treatments present in the clinic (Junttila 
and Sauvage, 2013).  
 
Inhibition of angiogenesis by targeting VEGF signaling is an alternative 
approach for normalizing the tumor microenvironment (Goel and Mercurio, 
2013). In high-grade glioma, a selective inhibitor of VEGF signaling 
downregulated tumor growth and tumor cell infiltration (Vajkoczy et al., 2000). 
A humanized monoclonal anti-VEGF antibody, bevacizumab (Avastin), is the 
first US Food and Drug Administration (FDA) approved molecule that targets 
VEGF pathway (Ferrara et al., 2004). In combination with other agents or as 
monotherapy, bevacizumab showed beneficial effects for the treatment of 
metastatic colorectal cancer, advanced non-small-cell lung cancer, metastatic 
renal cancer, ovarian cancer, advanced metastatic cervical cancer and 
recurrent glioblastoma multiforme (Junttila and Sauvage, 2013). However, 
recent preclinical studies have suggested that anti-angiogenic drugs targeting 
the VEGF pathway may accelerate metastasis and decrease the overall 
survival in mice indicating the development of an adaptive resistance (Ebos et 
al., 2009; Paez-Ribes et al., 2009). In line with these studies, some patients 
with recurrent malignant glioma treated with bevacizumab had more invasive 
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tumors (De Groot et al., 2010). On the other hand, a recent clinical study 
shows that VEGF receptor tyrosine kinase inhibitor, Sunitinib does not 
accelerate tumor growth and does not shorten patient survival (Blagoev et al., 
2013). Alternatively, trastuzumab (herceptin), a monoclonal antibody against 
the cell surface receptor HER2 (human epidermal growth factor receptor-2) 
has been reported to reduce the diameter and volume of tumor blood vessels, 
as well as vascular permeability, and to slow down the tumor growth in an 
experimental breast cancer mouse model (Izumi et al., 2002). Besides, 
antibody-drug conjugates (ADCs) that enable targeted delivery of cytotoxic 
drugs with antibodies that selectively bind to tumor-associated antigens 
represent a promising strategy for increasing the therapeutic benefit for 
patients (Casi and Neri, 2012). Antigens expressed in the tumor stroma 
around the newly formed blood vessels are common targets in ADC 
technology. Antibodies against tumor vascular specific isoforms of FN (FN-
EDB and FN-EDA) (Villa et al., 2008) and TNC (A1) (Brack et al., 2006) serve 
as promising candidates for the development of ADCs.   
 
1.1.5 Radiation-induced modifications of the tumor microenvironment 
Ionizing radiation therapy is used as a routine method in cancer treatment. 
Radiation causes DNA damage directly by ionization or indirectly by the 
generation of reactive oxygen species. As a result, tumor cells undergo p53-
mediated apoptosis (Gudkov and Komarova, 2003). Furthermore, radiation 
induces apoptosis in tumor-associated endothelial cells, thus suppresses 
tumor angiogenesis and tumor growth (Ruegg et al., 2011). However, under 
certain circumstances, radiation exposure may alter the tissue 
microenvironment and contribute to metastasis. Radiation triggers several 
cellular mechanisms including ECM remodeling through the secretion of 
proteases, cytokines and growth factors, and recruitment of inflammatory cells 
(Barcellos-Hoff et al., 2005, Kuonen et al., 2012b). Furthermore, by 
suppressing angiogenesis, radiation results in hypoxia within the tumor tissue, 
which is associated with an aggressive tumor phenotype  (Ruegg et al., 
2011). Cancer cells that survive ionizing radiation can be radioresistant and   
cause tumor recurrence in cancer patients, and relapse after radiotherapy is 
often associated with increased local invasion, metastatic spread to lymph 
	
   18	
  
nodes and distant organs, and poor prognosis (Ruegg et al., 2011; Li et al., 
2014).  
 
Experiments of different research groups revealed that the irradiated 
microenvironment induces the metastatic potential of tumor cells, a 
phenomenon that is known as “tumor bed effect” (Ruegg et al., 2011). When 
mammary epithelial cells were injected into the mammary fat pads of pre-
irradiated mice, the tumor size and incidence was higher compared with non-
irradiated hosts (Barcellos-Hoff and Ravani, 2000). Likewise, immortal 
myogenic cell lines have been reported to form tumors faster in irradiated than 
in non-irradiated host muscle (Morgan et al., 2002). Experimental tumors 
growing in irradiated tissues had a higher tendency to metastasize compared 
to tumors growing in a normal stroma (Milas et al., 1988). In another study, it 
was shown that ionizing radiation exposure induces senescence in human 
mammary stromal fibroblasts, alters the cytoskeletal network and upregulates 
ECM degrading MMP expression (Tsai et al., 2005). Furthermore, when 
breast carcinoma cells were grown with irradiated fibroblasts in three-
dimensional co-culture they showed increased invasive growth (Tsai et al., 
2005). Subcutaneous tumors growing within pre-irradiated mice had 
increased hypoxia and lung metastasis formation compared with tumors 
growing in non-irradiated control mice (Monnier et al., 2008). Cells derived 
from tumors grown in pre-irradiated beds preserved their metastatic capacity 
when injected into non-irradiated mice (Monnier et al., 2008). The study of 
Monnier et al. (2008) shows that pre-irradiated tumor stroma selects for tumor 
cells that have a high metastatic potential. CYR61/CCN1, the first member of 
the CCN matricellular protein family was identified as one of the genes linked 
to metastasis of tumor cells growing in a pre-irradiated bed (Monnier et al., 
2008). Likewise, in an orthotopic breast cancer model, tumors growing in pre-
irradiated mammary tissue had reduced angiogenesis and were more 
hypoxic, invasive, and metastatic to the lungs and to lymph nodes compared 
with control tumors (Kuonen et al., 2012a).  
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Previously it has been shown that prevention of apoptosis in endothelial cells 
attenuates the tumor response to radiotherapy (Garcia-Barros et al., 2003). 
Mauceri et al. (1998) reported that combined administration of ionizing 
radiation and anti-angiogenic treatment with angiostatin increases endothelial 
cell death in vitro and improves tumor management without increasing toxicity 
towards normal tissue (Mauceri et al., 1998). These results are clinically 
relevant. Anti-angiogenic drugs, such as bevacizumab that interfere with 
endothelial cell survival pathways and sensitize endothelial cells to ionizing 
radiation-induced death would improve the therapeutic response to 
radiotherapy (Wachsberger et al., 2004). On the other hand, anti-angiogenic 
therapies that reduce the blood supply might cause hypoxia within the tumor 
tissue and promote metastasis (Steeg, 2003).  
 
Several signaling pathways have been reported to mediate tumor progression 
after radiotherapy (Kuonen et al., 2012b). The WNT/β-catenin pathway can be 
aberrantly activated by irradiation exposure, resulting in the transcription of β-
catenin target genes (Kim et al., 2012). Aberrant activation of the WNT/β-
catenin signaling pathway has been implicated in radioresistance in mammary 
progenitor cells (Chen et al., 2007) and in an orthotopic model of glioblastoma 
(Kim et al., 2012). Following irradiation, mammary progenitor cells displayed 
higher levels of β-catenin (Chen et al., 2007). Glioblastoma cells isolated from 
xenograft tumors after irradiation had a more aggressive phenotype compared 
with control tumor cells (Kim et al., 2012). Transcriptome analyses using 
glioblastoma xenograft tumors with or without in vivo ionizing radiation 
treatment revealed that Wnt pathway associated genes were activated upon 
irradiation (Kim et al., 2012). Among the differentially expressed genes, WNT1 
inducible signaling pathway protein 1 (WISP1) showed the highest fold 
change (Kim et al., 2012). In line with these observations, upregulation of 
WISP1 was associated with poor clinical outcome in glioblastoma patients 
(Kim et al., 2012). A recent study shows that fractionated irradiation increases 
β-catenin activity and the expression of its target genes, including WISP1 in 
esophageal cancer cells (Li et al., 2014). WISP1 expression contributes to the 
development of fractionated irradiation-induced radioresistance (Li et al., 
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2014). Future work will reveal further mechanistic details of how radiation 
contributes to tumor progression.  
 
1.2 The family of CCN proteins 
 
1.2.1 Functions and mechanism of action of CCN proteins: 
ECM regulates cell behavior through different extracellular signaling 
molecules such as growth factors, cytokines, chemokines and extracellular 
enzymes, as well as directly by binding to and signaling through cell-surface 
receptors (Jun and Lau, 2011). A group of ECM proteins, known as 
matricellular proteins, are dynamically expressed and serve regulatory roles 
rather than contributing to the organization and structure of the vertebrate 
matrix (Bornstein and Sage, 2002; Jun and Lau, 2011). Thrombospondins, 
SPARC, hevin, osteopontin, tenascins, periostin, R-spondins, small leucine 
rich proteoglycans (SLRPs), the short fibulins including hemicentin, galectins, 
autotaxin, pigment epithelium derived factor (PEDF), plasminogen activator 
inhibitor-1 (PAI-1), and members of the CCN family are known matricellular 
proteins (Murphy-Ullrich and Sage, 2014). Matricellular proteins are usually 
expressed at high levels during development and in response to injury 
(Bornstein and Sage, 2002).  
 
The acronym “CCN” is derived from the names of the first three members of 
the family: CYsteine-Rich 61 (CYR61) (O’Brien et al., 1990), Connective 
Tissue Growth Factor (CTGF) (Bradham et al., 1991) and Nephroblastoma 
OVer-expressed (NOV) (Joliot et al., 1992), which are named as CCN1, 
CCN2 and CCN3, respectively (Brigstock et al., 2003). Together with three 
WNT1 inducible signaling pathway proteins, WISP1/CCN4, WISP2/CCN5 and 
WISP3/CCN6 they comprise a family of six homologous proteins (Chapter 
4.2, Supplementary Figure 1) (Pennica et al., 1998; Chen and Lau, 2009). 
CCN proteins contain a particularly high number of conserved cysteine 
residues, which corresponds to ~10% of the entire protein (Jun and Lau 
2011).  
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Early studies raised the idea that CCN proteins are polypeptide growth factors 
(Bradham et al., 1991; Frazier et al., 1996). Later on, combined work within 
the CCN field defined CCNs as matricellular proteins that are involved in 
regulating cell-ECM interactions and cellular responses to extracellular stimuli 
(Leask and Abraham, 2006; Chen and Lau, 2009). CCN proteins regulate 
several cellular processes like cell adhesion, migration, proliferation, 
differentiation, apoptosis, survival, and senescence as well as ECM 
production and gene expression (Yeger and Perbal, 2007; Jun and Lau, 
2011). At the organismal level, CCN proteins are implicated in 
embryogenesis, especially in cardiovascular, skeletal, renal and neuronal 
development (Chen and Lau, 2009; Jun and Lau, 2011). In postnatal 
development and in the adulthood, under normal situations CCN proteins are 
expressed at low levels in most tissues, however the expression increases 
upon inflammation, wound healing and fracture repair in bones and injury 
repair in many organs (Chen and Lau, 2009; Jun and Lau, 2011). 
Deregulation of CCN proteins results in various pathologies related to chronic 
inflammation and tissue injury, including arthritis, fibrosis and cancer, as well 
as cardiovascular diseases, diabetic nephropathy and retinopathy (Jun and 
Lau, 2011). The genes encoding CCN proteins are sensitive to growth factors, 
steroid hormones, and inflammatory cytokines such as interleukin 1 (IL-1) and 
tumor necrosis factor (TNF), as well as to environmental changes, like oxygen 
deprivation, ultraviolet light exposure, radiation, mechanical stress (e.g. 
mechanical stretch and tensile forces), and bacterial and viral infections  
(Chen and Lau, 2009; Jun and Lau, 2011).  
 
Variants of CCN proteins have been detected in normal and pathological 
conditions, and some truncated CCNs were reported to serve as effective 
biomarkers for various diseases (Perbal, 2009). Alternative splicing 
(Hirschfeld et al., 2009; Perbal, 2009), proteolysis by MMPs (Dean et al., 
2007) or post-translational modifications, such as glycosylation (Yang et al., 
2011) are involved in the generation of different CCN isoforms with distinct 
biological functions.  
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CCN proteins mediate their activities through interaction with various cell 
surface receptors and co-receptors (Figure 6). These receptors include, many 
different integrins, heparan sulfate proteoglycans (e.g. syndecan 4), 
lipoprotein receptor-related proteins, and Notch (Segarani et al., 2001; Chen 
and Lau, 2009). Unlike many other ECM proteins, CCN proteins do not 
contain the canonical RGD sequence that is required for integrin binding. 
Instead, they possess non-canonical binding sites for adhesion receptors (Jun 
and Lau, 2011). CCN proteins can physically interact with other ECM proteins 
including FN (Chen et al., 2004; Hoshijima et al., 2006), perlecan (Nishida et 
al., 2003), vitronectin (Francischetti et al., 2010) and dermatan sulfate 
proteoglycans (e.g. decorin and biglycan) (Desnoyers et al., 2001). Moreover 
CCNs can modulate the activity and bioavailability of several growth factors 
and inflammatory cytokines through functional and/or physical interaction 
(Chen and Lau, 2009; Jun and Lau, 2011). Binding of CCN proteins to VEGF 
(Inoki et al., 2002), FGF-2 (Nishida et al., 2011), TGF-β (Abreu et al., 2002) 
and bone morphogenetic proteins (BMPs) (Abreu et al., 2002) has been 
reported.  
 
 
 
Figure 6: CCN proteins interact with various cell surface receptors and extracellular proteins. 
Interacting domains are shown. CCN2 binds to the extracellular matrix proteins, fibronectin 
and perlecan through its CT domain, as well as to growth factors such as bone 
morphogenetic proteins (BMPs) and transforming growth factor-β (TGF-β) through the VWC 
domain, and vascular endothelial growth factor (VEGF) through the TSP and CT domains. 
CCN3 has been shown to bind to Notch receptor through its CT domain. (Adapted from Chen 
and Lau, 2009). 
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1.2.2 CCN proteins in embryonic development 
Targeted disruption of genes encoding CCN proteins in mice have been 
achieved. Among the different transgenic animals, the most commonly 
observed phenotype is defective cardiovascular and skeletal development 
(Chen and Lau, 2009; Jun and Lau, 2011). Targeted disruption of CCN1 
results in embryonic lethality with severe cardiovascular defects in mice (Mo 
et al., 2002). CCN2-null mice are neonatal lethal due to respiratory defects 
that occur as a secondary cause of severe skeletal malformations (Ivkovic et 
al., 2003). Transgenic mice that produce mutant CCN3 lacking the VWC 
domain instead of the full length CCN3 have been constructed (Heath et al., 
2008). Less than 50% of transgenic mice are viable and they show defects in 
the appendicular and axial skeleton, severe joint malformation, and abnormal 
remodeling of the endocardial cushions with associated cardiac septal defects 
(Heath et al., 2008). In another study, the entire CCN3 was inactivated by 
homologous recombination. CCN3-knockout (KO) animals were viable and 
mostly normal, exhibiting only modest and transient sexually dimorphic 
skeletal abnormalities (Canalis et al., 2010). WISP1/CCN4 KO mice show 
delayed wound healing and cartilage development compared to wildtype 
counterparts and they have lower expression levels of FN and Type I collagen 
(Seventh international workshop on the CCN family of genes, 2014) 
Moreover, dermal fibroblasts isolated from WISP1-KO mice show impaired 
cell proliferation and migration in vitro. Furthermore, WISP1 plays an 
important role in bone formation and maintenance. Conditional transgenic 
mice that overexpress human WISP1 in mineralized tissues have increased 
bone mineral density, trabecular thickness, and bone volume over wild-type 
controls (Ono et al., 2011). Mice were viable and no major abnormalities were 
observed, however female transgenics were unable to give birth (Ono et al., 
2011). Alteration of CCN5 expression in either direction leads to embryonic 
lethality: both CCN5-null mice and transgenic mice overexpressing CCN5 do 
not implant properly and die at or before the gastrulation stage suggesting 
that CCN5 plays a critical role in early embryonic development (Russo and 
Castellot, 2010, mentioned as unpublished data). Loss-of-function mutations 
in the CCN6 gene in humans has been reported to cause autosomal 
recessive skeletal disease progressive pseudorheumatoid dysplasia, a 
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juvenile-onset degenerative disease of the joints (Hurvitz et al., 1999) 
However, CCN6-knockout mice or mice that overexpress CCN6 do not exhibit 
any observable phenotype compared to wildtype animals (Kutz et al., 2005).  
 
1.2.3 CCN proteins in cancer and potential therapeutic approaches 
Aberrant expression of CCN proteins have been identified in cancers of 
numerous organs and tissues, including breast, colorectal, gallbladder, 
gastric, ovarian, pancreatic, and prostate cancers, gliomas, hepatocellular 
carcinoma, non-small cell lung and squamous cell carcinoma, lymphoblastic 
leukemia, melanoma, and cartilaginous tumors (Chen and Lau, 2009).  
 
CCN proteins can promote tumorigenesis and tumor progression by 
enhancing angiogenesis and stimulating tumor cell survival (Babic et al., 
1998; Shimo et al., 2001; Chen and Lau, 2009). In particular, expression of 
CCN1 and CCN2 promotes tumor vascularization, EMT, and tumor cell 
survival through the induction of anti-apoptotic proteins (Jun and Lau, 2011). 
Furthermore, CCN2 has been identified as one of the genes overexpressed in 
human breast cancer cell lines with elevated osteolytic bone metastasis (Kang 
et al., 2003). In support of that, treatment of nude mice with an anti-CCN2 
monoclonal antibody decreased osteolytic bone metastasis of human breast 
cancer cell xenografts (Shimo et al., 2006). Administration of a neutralizing 
CCN2-specific humanized monoclonal antibody, FG-3019 (FibroGen), 
attenuates tumor growth, lymph node metastasis, and tumor angiogenesis in 
xenograft (Dornhofer et al., 2006) and orthotopic (Aikawa et al., 2006) mouse 
models of pancreatic cancer. FG-3019 has been the subject of clinical trials in 
patients with idiopathic pulmonary fibrosis, liver fibrosis and pancreatic cancer 
(Yeger and Perbal, 2007). CCN3 expression has been associated with higher 
risk of developing metastasis and poor prognosis in Ewing’s sarcoma (Perbal 
et al., 2009), melanoma (Vallacchi et al., 2008), and breast cancer (Ghayad et 
al., 2009). Likewise, aberrant WISP1/CCN4 expression has been associated 
with cancer. This is summarized and dicussed in our review entitled 
“CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): a focus on its 
role in cancer” following this chapter. 
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Depending on the tumor type and tissue context, some tumor suppressive 
effects of CCN proteins have also been demonstrated (Jun and Lau, 2011). 
For instance, it was shown that CCN1 expression promotes growth arrest in 
non-small cell lung carcinoma cells in vitro, and when these cells are injected 
into the nude mice they form smaller tumors compared with the control cells 
(Tong et al., 2001). CCN2 inhibits metastasis and invasion of human lung 
adenocarcinoma (Chang et al., 2004), suppresses liver metastasis of 
colorectal cancer, and its expression is correlated with good prognosis (Lin et 
al., 2005). Ectopic expression of CCN3 inhibits the proliferation of glioma cells 
in vitro and tumor growth in vivo (Gupta et al., 2001). In the late nineties, 
WISP1/CCN4 was identified as Elm1 (expressed in low-metastatic cells) that 
can suppress the in vivo growth and metastatic potential of mouse melanoma 
cells (Hashimoto et al., 1998). CCN5, named COP1, has been reported to be 
a negative regulator of cell transformation (Zhang et al., 1998). Later, it has 
been shown that CCN5 reduces the proliferative and invasive phenotypes of 
poorly differentiated breast cancer cells and plays a role in maintaining the 
differentiated, non-invasive phenotype of these cells (Fritah et al., 2008). In 
breast adenocarcinoma, CCN5 mRNA and protein levels are reduced as the 
cancer progresses from a noninvasive to invasive type, and CCN5 expression 
is inversely correlated with lymph-node positivity (Banerjee et al., 2008). 
CCN6 has been reported to suppress in vivo tumor cell growth, invasion and 
angiogenesis, and it has been shown that loss of CCN6 expression 
contributes to inflammatory breast cancer phenotype (Kleer et al., 2002). 
Moreover, mice bearing CCN6 expressing tumors have a longer survival rate 
compared to the controls (Kleer et al., 2002).  
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1.2.4 CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): A 
focus on its role in cancer 
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license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The WNT1 inducible signaling pathway protein 1, also known as
CN4 or Elm1 is a cysteine-rich, matricellular protein that belongs
o the CCN family (Hashimoto et al., 1998; Jun and Lau, 2011). The
cronym “CCN” is derived from the names of the first three fam-
ly members: CYsteine-Rich 61 (CYR61/CCN1), Connective Tissue
rowth Factor (CTGF/CCN2) and Nephroblastoma OVer-expressed
NOV/CCN3) (Jun and Lau, 2011). WISP1 was originally identified
s a downstream target of WNT1 and -catenin, and contributes to
-catenin-mediated tumorigenesis (Pennica et al., 1998; Xu et al.,
000).
Deregulation of WISP1 signaling may  result in various patholo-
ies including osteoarthritis, fibrosis and cancer. In a previous
eview, the role of WISP1 in development and disease was  dis-
ussed (Berschneider and Konigshoff, 2011). Here, we  focus on the
mpact of WISP1 in tumor progression and summarize recent stud-
es based on which WISP1 holds promise as a diagnostic marker
nd/or therapeutic target.∗ Corresponding author at: Friedrich Miescher Institute for Biomedical Research,
aulbeerstrasse 66, CH-4058 Basel, Switzerland. Tel.: +41 61 697 24 94.
E-mail address: Irem.Guerbuez@fmi.ch (I. Gurbuz).
ttp://dx.doi.org/10.1016/j.biocel.2015.03.007
357-2725/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article un2. Structure
CCN proteins possess a conserved modular structure consist-
ing of an amino-terminal secretory signal peptide followed by four
structural domains: an insulin-like growth factor binding protein-
like module (IGFBP), a von Willebrand factor type C repeat (VWC), a
thrombospondin-homology type 1 repeat (TSP1), and a C-terminal
cysteine-knot-containing (CT) domain (Jun and Lau, 2011). A non-
conserved, protease-sensitive hinge region is located between VWC
and TSP1 domains (Jun and Lau, 2011). Except CCN5, which lacks
the CT module (Pennica et al., 1998), all CCN proteins contain the
four complete structural modules (Fig. 1).
CCN protein variants that lack certain domains play distinct bio-
logical roles and have been implicated in several pathologies (Jun
and Lau, 2011). Alternative splicing results in WISP1v lacking exon
3 and thus the VWC  domain (Tanaka et al., 2001). This truncated
variant has been detected in scirrhous gastric carcinoma (Tanaka
et al., 2001) and invasive cholangiocarcinoma (Tanaka et al., 2003).
Moreover, in addition to full length WISP1 and WISP1v, two
hepatocellular carcinoma cell lines and a human chondrosarcoma-
derived chondrocytic cell line express further shorter variants,
WISP-1ex3-4 (Cervello et al., 2004) and WISP1vx (Yanagita et al.,
2007), respectively. Models of all described WISP1 variants are
shown in Fig. 1.
The full length WISP1 protein consists of 367 aminoacids with
a predicted molecular mass of 40 kDa, has 38 conserved cysteine
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Modular structure of CCN proteins. Full length CCN4/WISP1 and truncated
variants are shown in orange. WISP1v is a gene product formed by alternative
splicing that lacks exon 3, hence the VWC  domain (Tanaka et al., 2001). WISP1vx
lacks VWC  and TSP1 domains and part of the IGFBP domain (23 bp shorter than the
full-length exon). Owing to a frame-shift, the IGFBP/CT fusion coding frame is not
translated properly after the alternative splice site. The protein product is a single
IGFBP module, in which eight C-terminal amino acid residues are removed, and an
extra 14 residues are added in their place (Yanagita et al., 2007). WISP1ex3-4 splice
variant is a product of joining of exons 2 and 5 with a frameshift that led to a prema-
ture  stop. As a result, the predicted protein has only the first module (Cervello et al.,
2004). SP: signal peptide, IGFBP: insulin growth factor binding protein, VWC: van
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eferred to the web  version of this article.)
esidues and four potential N-linked glycosylation sites (Pennica
t al., 1998; Berschneider and Konigshoff, 2011). Indeed, it was
bserved that WISP1 is glycosylated and that the pattern of gly-
osylation differs between cancer cells and normal fibroblasts
discussed in Soon et al., 2003). Furthermore, overexpression of
ISP1 in mammalian cells and external addition of the recombi-
ant WISP1 produced in Escherichia coli (E.coli), lacking mammalian
ost-translational modifications, had different biological effects
n cells (Inkson et al., 2008). According to these results, post-
ranslational modifications seem to affect WISP1 function.
. Regulation and biological function
WISP1 expression is regulated by different signaling pathways
nd is sensitive to different biochemical cues as well as extracel-
ular perturbations. Previous work from our group showed that
ISP1 is induced by megakaryoblastic leukemia protein 1 (Mkl1)
n a serum response factor-independent, SAP domain-dependent
anner and it was found to be part of a gene signature implicated
n cell proliferation and motility elevated in breast cancer patients
ith poor survival (Gurbuz et al., 2014). Many genes of this sig-
ature, including WISP1 were shown to be mechano-responsive in
yclically stretched mouse mammary epithelial cells (Gurbuz et al.,
014). Furthermore, WISP1 was induced by mechanical stretch
n lung alveolar epithelial cells (Heise et al., 2011). Additionally,
ellular processes that modulate Wnt/-catenin signaling regu-
ate the expression of the downstream target genes, including
ISP1. In a rat model of alcohol-induced liver disease, it was  found
hat chronic alcohol feeding induces Wnt/-catenin signaling and
ISP1 upregulation, which in turn increases hepatocyte prolifer-
tion and promotes tumorigenesis (Mercer et al., 2014). A recent
tudy shows that overexpression of WISP1 contributes to the
evelopment of fractionated irradiation-induced radioresistance
n esophageal cancer cells in vitro and in vivo, and links WISP1 to
adiation, a phenomenon that is known to activate Wnt/-catenin
ignaling (Li et al., 2014).CCN family members regulate complex biological processes dur-
ng embryogenesis, wound healing and tissue repair (Berschneider
nd Konigshoff, 2011). WISP1 expression has been observed in
he developing skeleton and during bone healing in the adulthoodl of Biochemistry & Cell Biology 62 (2015) 142–146 143
(French et al., 2004). WISP1 mRNA was detected in the adult heart,
kidney, lung, pancreas, placenta, ovary, small intestine, and spleen.
Low or no expression was  seen in the brain, liver, skeletal mus-
cle, colon, peripheral blood leukocytes, prostate, testis, or thymus
(Pennica et al., 1998). WISP1 knockout (KO) mice show delayed
wound healing and cartilage development compared to wildtype
mice (Seventh international workshop on the CCN family of genes,
2014). Many reports support a function of WISP1 in tumor cell pro-
liferation, migration and survival in vitro, as well as tumor growth
and metastasis in vivo.
Recombinant WISP1 (Source: E. coli) treatment is shown to pro-
mote mitosis in irradiated esophageal cancer cells (Li et al., 2014)
and in human bone marrow stromal cells (hBMSCs; Inkson et al.,
2008). Likewise, recombinant WISP1 treatment (Source: mouse
myeloma cells) induces proliferation of alveolar epithelial cells and
adenocarcinomic human alveolar basal epithelial cells (Konigshoff
et al., 2009). Overexpression of WISP1 variants increases the growth
rate of mouse embryonic fibroblasts (Tanaka et al., 2001), rat kidney
fibroblasts (Xu et al., 2000), hBMSCs (Inkson et al., 2008) and human
esophageal cancer cells (Nagai et al., 2011). Dermal fibroblasts iso-
lated from KO mice show impaired cell proliferation and migration
in vitro (Seventh international workshop on the CCN family of
genes, 2014). This seems to be different for melanoma cells. Mouse
melanoma cells expressing a high level of WISP1 showed slightly
slower in vitro and in vivo growth rates than cells expressing a low
level of the protein (Hashimoto et al., 1998). Furthermore, a recent
study shows that supplementation of recombinant WISP1 (Source:
mouse myeloma cells) in the culture medium has an inhibitory
effect on melanoma cell growth while migration is not affected
(Shao et al., 2011). The number of migrated gastric carcinoma cells
(Tanaka et al., 2001) and cholangiocarcinoma cells (Tanaka et al.,
2003) increased with exposure to WISP1v. Human prostate cancer
cells (Ono et al., 2013) and chondrosarcoma cells (Hou et al., 2011)
show increased migration and invasion toward WISP1 recombi-
nant protein (Source: E. coli), which suggests that WISP1 could
have chemotactic properties and might influence the homing of
cancer cells in case of metastasis. In support of these results, it
was reported that recombinant WISP1 treatment (Source: mouse
myeloma cells) induces epithelial to mesenchymal transition by
regulating marker gene expression and by increasing cell migra-
tion (Konigshoff et al., 2009). In contrast, WISP1 overexpression in
lung cancer cells leads to an inhibition of in vitro cell invasion and
motility, as well as lung metastasis (Soon et al., 2003).
How exactly WISP1 modulates cellular function and through
which receptors it transmits signals is unknown. Different inte-
grins have been identified as functional receptors for some CCN
proteins (Jun and Lau, 2011). Recent studies have confirmed the
functional and physical interaction of WISP1 with integrins. It was
shown that WISP1 physically interacts with 51 Integrin, and that
its overexpression increases 5 expression in bone marrow stro-
mal  cells (Ono et al., 2011). Two  other binding partners of WISP1
are decorin and biglycan, members of a family of small leucine-
rich proteoglycans present in the extracellular matrix of connective
tissue (Desnoyers et al., 2001).
4. Expression in cancer and role in prognosis
CNN proteins are aberrantly expressed in numerous diseases,
including cancer (Jun and Lau, 2011). Generally, WISP1 expression
has been associated with the promotion of tumor progression, and
in a range of tumor types high WISP1 expression has been identified
within the tumor tissue compared to the healthy organ (summa-
rized in Table 1). Likewise, transcript profiling studies available
from the Oncomine database reveal increased WISP1 transcript
levels in a wide variety of cancers (Fig. 2). Moreover, WISP1 cor-
relates with poor prognosis in the majority of cancer incidences.
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Fig. 2. Aberrant WISP1 expression has been identified in different tumor types. Oncomine differential gene expression analysis (Normal vs Cancer, Human Genome U133
Affymetrix Array data, Affymetrix Probe ID: 206796 at, www.oncomine.org) revealed that WISP1 mRNA expression levels are higher within tumor tissue compared with
normal tissue in most of the cancer incidences. Results are represented with a box plot: the thick line represents the median value. Minimal and maximal values are plotted
as  dots. Fold changes (FC) between normal and tumor tissues are indicated. Number of samples analyzed is shown within brackets.
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Table  1
Cancer type Expression level
tumor versus
normal
Correlation of
WISP1 level
with prognosis
Reference
Breast Cancer Higher
Not known
Higher
Bad
Good
Not known
Xie et al. (2001),
Davies et al. (2007),
Klinke (2014)
Gastric
Adenocarcinoma
Higher Not known Bizama et al. (2014)
Brain Cancer Higher Bad Xie et al. (2004)
Pancreatic Cancer Higher Not known Cao et al. (2004),
Badea et al. (2008)
Head and Neck
Cancer
Higher Not known Chuang et al.
(2013)
Lung
Adenocarcinoma
Higher Not known Chen et al. (2007),
Yang et al. (2014)
Colorectal Cancer Higher Good
Bad
Khor et al. (2006),
Davies et al. (2010)
Rectal Cancer Higher Bad Tian et al. (2007)
Colon
Adenocarcinoma
Higher Not known Pennica et al.
(1998)
Chondrosarcoma Higher Not known Hou et al. (2011)
Endometrial
Endometrioid
Carcinoma
Higher Bad Tang et al. (2011)
Esophageal Cancer Higher Bad Nagai et al. (2011)
Scirrhous Carcinoma Higher Not known Tanaka et al. (2001)
Cholangiocarcinoma Higher Bad Tanaka et al. (2003)
Prostate Cancer Higher Good Ono et al. (2013)
Melanoma Lower Not known Shao et al. (2011)
Aggressive
Fibromatosis
Higher Bad Skubitz and Skubitz
(2004), Misemer
et al. (2013)
Publication details only provided for reports that are not listed under References:
Badea et al. (2008) Hepatogastroenterology 55(88): 2016–2027; Bizama et al. (2014)
Int  J Cancer 134(4): 755–764; Cao et al. (2004) Cancer Biol Ther 3(11): 1081–1089;
Chen et al. (2007) PLoS One 2(6): e534; Chuang et al. (2013). PloS One 8(10): e78022;
Klinke (2014) PLoS Comput Biol 10(1): e1003409; Misemer et al. (2014) Cancer Med
3(1): 81–90; Skubitz and Skubitz (2004) J Lab Clin Med  143(2): 89–98; Tang et al.
(2011) J Obstet Gynaecol Res 37(6): 606–612; Xie et al. (2004) Clin Cancer Res 10(6):
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a072–2081; Yang et al. (2014) Cancer Gene Ther 21(2): 74–82.
xceptionally, WISP1 levels in the primary prostate cancer stroma
nd in the patient’s sera decreases with increasing severity of the
ancer (Ono et al., 2013). In some cancers a role for WISP1 levels in
rognosis is controversial. For example, two independent studies
how that higher level of WISP1 is associated with poor histological
ifferentiation, tumor aggressiveness and poor clinical outcome in
olorectal and rectal carcinomas (Tian et al., 2007; Davies et al.,
010). In contrast, Khor et al. (2006) links WISP1 expression to
ell-differentiated colorectal tumors. A similar discrepancy is seen
hen analyzing WISP1 expression in breast cancer. Davies et al.
2007) show that the transcript levels are lower in node-positive
nd high-grade tumors and in patients with poor clinical outcome.l of Biochemistry & Cell Biology 62 (2015) 142–146 145
These results contradict a previously published study where it was
shown that high WISP1 mRNA levels correlate with an advanced
stage of breast cancer (Xie et al., 2001).
The crosstalk between tumor cells and the tumor stroma has
a remarkable impact on tumor progression. Cancer cells secrete
growth factors and proteases to activate surrounding stromal
cells to form a supportive environment for tumor progression
(Mueller and Fusenig, 2004). Activated fibroblasts, also known
as carcinoma-associated fibroblasts (CAFs), in turn modulate the
tumor microenvironment by secreting extracellular matrix pro-
teins and matrix degrading enzymes (Mueller and Fusenig, 2004).
WISP1 is upregulated in CAFs compared with fibroblasts in the
adjacent normal tissue in colon cancer (Rupp et al., 2014) and in
breast cancer (Bauer et al., 2010). In many cancers and in WNT1
transgenic mice, WISP1 is localized to the tumor stroma surround-
ing the cancer cells (Pennica et al., 1998; Tanaka et al., 2001, 2003;
Bauer et al., 2010; Ono et al., 2013; Rupp et al., 2014). WISP1 over-
expressing rat kidney fibroblasts are not able to form colonies in
the soft agar, however when they are injected into nude mice
they form tumors (Xu et al., 2000). These results suggest that the
paracrine interactions may  have a positive regulatory effect on
tumor growth and progression. In contrast, Shao et al. (2011) show
that WISP1 expression is stronger in quiescent fibroblasts com-
pared with melanoma cells and “melanoma activated fibroblasts”,
which suggest a negative regulatory effect of paracrine WISP1
signaling in melanoma.
5. Possible applications in cancer diagnosis and therapy
The differential expression status of WISP1 between the tumor
tissue and normal healthy tissue, as well as the correlation of its
expression with clinical outcome makes WISP1 a promising target
for the evaluation of clinical diagnosis and prognosis of cancers.
In particular, WISP1 could be exploited to predict different
stages of prostate cancer and thus serve as an alternative biomarker
to Prostate Specific Antigen (Ono et al., 2013). In early stages of
prostate cancer, WISP1 was detected not only in tissue biopsies but
also in sera from patients (Ono et al., 2013). In the future, WISP1
might be used as a tumor marker that is easy to detect by a simple
blood test.
In addition to its diagnostic potential, WISP1 can be utilized as a
therapeutic target. Targeting WISP1 by neutralizing antibodies neg-
atively regulates progression of certain cancers, including prostate
cancer and recurrent esophageal carcinoma after radiotherapy. In
mouse xenograft models of human prostate cancer cells, treatment
with WISP1 neutralizing antibodies reduces tumor growth as well
as metastasis to bone (Ono et al., 2013). In another study, deple-
tion of WISP1 by neutralizing antibodies cause mitotic catastrophe
in radioresistant esophageal cancer cells without affecting normal
cancer cells (Li et al., 2014). Blocking WISP1 interaction with its
partners, such as cancer-associated integrins, might be another
therapeutic strategy to inhibit WISP1-mediated tumor progres-
sion. Furthermore, finding ways to down-regulate its expression
might open new treatment opportunities. Since WISP1 expression
is known to be induced by Wnt/-catenin signaling as well as by
mechanical signals mediated by Mkl1, drugs constraining these
pathways may  help to alleviate WISP1-mediated effects on cancer
progression.
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1.3 Aim of the thesis: 
Our lab is interested in understanding extracellular matrix (ECM)-cell 
interactions and the role of these interactions in cancer progression. 
Megakaryoblastic leukemia 1 (MKL1) belongs to myocardin related 
transcription factor family and functions as a co-activator for serum response 
factor (SRF) (Scharenberg et al., 2010). It plays role in diverse biological 
processes, including cell adhesion, spreading and motility (Medjkane et al., 
2008). It has been shown that MKL1 is involved in tumor cell invasion and 
metastasis (Medjkane et al., 2008), and in transforming growth factor-β (TGF-
β)-induced epithelial-mesenchymal transition (EMT) (Morita et al., 2007). 
Through Rho GTPase/ actin signaling pathway, MKL1 forms a link between 
the ECM and the nucleus and functions as a mediator of 
mechanotransduction. Previous work from our group revealed a novel 
function of MKL1 and showed that MKL1 may act as a bona fide transcription 
factor mediating SRF-independent, SAP-domain-dependent induction of 
Tenascin-C (TNC) transcription (Asparuhova et al., 2011). In the present 
study our goal is to identify additional SAP-domain dependent MKL1 target 
genes that are co-regulated with TNC and to investigate whether such genes 
are implicated in cancer progression. For our analyses we used mutant MKL1 
constructs that were transfected into HC11 mouse mammary epithelial cells 
(Figure 7) (Asparuhova et al., 2011).  
 
 
Figure 7: Mouse MKL1 constructs used in the study. The full-length constract contains all 
functional domains. mutB1 constract has a mutated B1 domain, which is involved in serum 
response factor interaction. ΔSAP constract lacks the SAP domain, which is the homology 
domain found in SAF-A/B, Acinus, PIAS. SAP domain is involved in DNA binding. (Adapted 
from Asparuhova et al., 2011). 	
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CHAPTER 2: RESULTS 
 
2.1 Published Manuscript 
“SAP domain-dependent Mkl1 signaling stimulates proliferation and cell 
migration by induction of a distinct gene set indicative of poor prognosis in 
breast cancer patients” 
 
Irem Gurbuz, Jacqueline Ferralli, Tim Roloff, Ruth Chiquet-Ehrismann and 
Maria B Asparuhova 
 
Molecular Cancer 2014, 13:22. 
 
My contribution: 
For this study, together with Maria B Asparuhova I designed and analyzed cell 
functional assays. I performed 5-bromo-2′-deoxyuridine (BrdU) incorporation 
assay to test the proliferation rate of HC11 cell strains. To investigate the cell 
motility, I performed Boyden Chamber migration assay. With the inputs of 
Jacqueline Ferralli and Maria B Asparuhova, I planned, performed and 
analyzed mechanical strain application experiments. Furthermore, I performed 
all qRT-PCR analyses and immunoblot experiments to test mRNA expression 
and protein expression, respectively. Finally, I contributed to the preparation 
of the manuscript. 
 
 
 
 
 
 
 
 
 
	
  
 	
  
Gurbuz et al. Molecular Cancer 2014, 13:22
http://www.molecular-cancer.com/content/13/1/22RESEARCH Open AccessSAP domain-dependent Mkl1 signaling stimulates
proliferation and cell migration by induction of a
distinct gene set indicative of poor prognosis in
breast cancer patients
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Background: The main cause of death of breast cancer patients is not the primary tumor itself but the metastatic
disease. Identifying breast cancer-specific signatures for metastasis and learning more about the nature of the genes
involved in the metastatic process would 1) improve our understanding of the mechanisms of cancer progression
and 2) reveal new therapeutic targets. Previous studies showed that the transcriptional regulator megakaryoblastic
leukemia-1 (Mkl1) induces tenascin-C expression in normal and transformed mammary epithelial cells. Tenascin-C is
known to be expressed in metastatic niches, is highly induced in cancer stroma and promotes breast cancer
metastasis to the lung.
Methods: Using HC11 mammary epithelial cells overexpressing different Mkl1 constructs, we devised a subtractive
transcript profiling screen to identify the mechanism by which Mkl1 induces a gene set co-regulated with
tenascin-C. We performed computational analysis of the Mkl1 target genes and used cell biological experiments to
confirm the effect of these gene products on cell behavior. To analyze whether this gene set is prognostic of
accelerated cancer progression in human patients, we used the bioinformatics tool GOBO that allowed us to
investigate a large breast tumor data set linked to patient data.
Results: We discovered a breast cancer-specific set of genes including tenascin-C, which is regulated by Mkl1 in a
SAP domain-dependent, serum response factor-independent manner and is strongly implicated in cell proliferation,
cell motility and cancer. Downregulation of this set of transcripts by overexpression of Mkl1 lacking the SAP domain
inhibited cell growth and cell migration. Many of these genes are direct Mkl1 targets since their promoter-reporter
constructs were induced by Mkl1 in a SAP domain-dependent manner. Transcripts, most strongly reduced in the
absence of the SAP domain were mechanoresponsive. Finally, expression of this gene set is associated with
high-proliferative poor-outcome classes in human breast cancer and a strongly reduced survival rate for patients
independent of tumor grade.
Conclusions: This study highlights a crucial role for the transcriptional regulator Mkl1 and its SAP domain during
breast cancer progression. We identified a novel gene set that correlates with bad prognosis and thus may help in
deciding the rigor of therapy.
Keywords: Myocardin-related transcription factor-A (MRTF-A), Metastasis, Cancer progression, Prognosis, Gene
regulation, Mechanical strain* Correspondence: Ruth.Chiquet@fmi.ch
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66,
Basel CH-4058, Switzerland
2Faculty of Science, University of Basel, Klingelbergstrasse 50, Basel CH-4056,
Switzerland
© 2014 Gurbuz et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gurbuz et al. Molecular Cancer 2014, 13:22 Page 2 of 16
http://www.molecular-cancer.com/content/13/1/22Background
Most breast cancer patients die from tumor metastases
and not from the primary tumor itself. Thus, the identi-
fication of genes and signaling pathways influencing the
metastatic process are of utmost importance. Once the
mechanisms leading to metastasis are uncovered, they
can in the future serve as a rational basis for prognosis
and intervention. From the beginning of its discovery,
tenascin-C has been strongly associated with tumorigen-
esis and cancer progression in many different types of
tumors (reviewed in [1,2]). Tenascin-C was not only
enriched in breast cancer tissue [3,4], but its high ex-
pression was part of a gene signature of breast cancers
metastasizing to the lung [5]. There is strong evidence
that tenascin-C contributes to the metastatic behavior of
breast cancer cells [6] by providing a niche for their
settlement in the lung [7,8]. The source of tenascin-C
can be the tumor cells themselves as well as the stromal
cells of the cancer microenvironment. Downregulation
of tenascin-C by miR-335 or shRNA in human cancer
cells in a mouse xenograft model inhibits metastasis for-
mation [7], and in tenascin-C-deficient mice, metastasis
formation of tenascin-C positive cancer cells is also
suppressed [9].
There are many signaling pathways inducing tenascin-C
expression (reviewed in [10]). Among these, mechanical
strain application in vivo as well as to cells in culture is
a potent stimulus to induce tenascin-C expression in fi-
broblasts [11,12]. We have recently shown that induc-
tion of tenascin-C by cyclic mechanical strain requires
the action of Mkl1 [13]. Mkl1 is a member of the
myocardin-related transcription factor family (MRTF)
and a well-known transcriptional co-activator of serum
response factor (SRF) [14-16]. SRF target genes, which
are regulated upon recruitment of MRTF cofactors, en-
code proteins involved in actin cytoskeletal function
that can either be structural (for example, actin) or re-
lated to actin dynamics (for example, talin 1) (reviewed
in [17,18]). However, Mkl1-mediated stretch-induced
tenascin-C expression in fibroblasts did not require
SRF, but instead depended on the potential DNA-
binding SAP domain of Mkl1. This implies a novel
mode of Mkl1 action as a bona fide transcription factor
in mechanotransduction [13]. Interestingly, normal and
transformed mouse mammary epithelial cells also ap-
pear to be highly sensitive to Mkl1 signaling, respond-
ing to Mkl1 overexpression with several fold induction
of tenascin-C [13].
The present study was designed to find SAP-dependent
Mkl1 target genes co-regulated with tenascin-C and to
analyze whether such genes could be indicative of specific
physiological states of cells that might be controlled by
mechanotransduction. For our study, we made use of the
HC11 mammary epithelial cell line. HC11 cells are capableof both self-renewal and differentiation and can be cul-
tured for unlimited time in an undifferentiated state [19],
the condition we used in our study. HC11 cells can recon-
stitute the ductal epithelium of a cleared mammary fat
pad in vivo with ductal, alveolar and myoepithelial cells,
illustrating their stem cell abilities [19,20]. In addition,
HC11 cells contain a mutated p53 gene that not only in-
creases the replicative potential of stem cells but confers
predisposition to mammary carcinoma [21]. Undifferen-
tiated HC11 cells share transcriptome signatures with
human breast cancer [22], supporting the relevance of
this model for breast cancer-related studies. We there-
fore concluded our study by investigating whether the
genes co-regulated with tenascin-C would also be impli-
cated in breast cancer progression.
Results
Screen for SAP-dependent Mkl1 target genes
We devised a screening method to identify genes co-
regulated with tenascin-C by Mkl1 in a SAP domain-
dependent manner without involvement of SRF. For this
purpose, we used HC11 mammary epithelial cells that
react strongly to the overexpression of Mkl1 with in-
duction of tenascin-C expression [13]. We compared
three HC11 strains that either overexpress the C-terminal
red fluorescent protein (RFP)-tagged full length Mkl1
(HC11-FL), Mkl1-RFP with a mutated SRF-interaction site
(HC11-mutB1) or Mkl1-RFP with a deletion of the SAP
domain (HC11-ΔSAP). None of the three Mkl1 variants
appear to be toxic to the cells, as we have not observed
any changes in viability or cell morphology. HC11-FL cells
were shown to overexpress Mkl1 7.1-fold above the en-
dogenous Mkl1 present in parental HC11 cells [13], and
were used as control cells in our study. All cell strains
were FACS sorted to express similar levels of Mkl1-RFP
proteins. These cells were used for transcript profiling
and gene lists of interest were established as shown in
Figure 1A, B. A scatter plot (Figure 1A) of all transcripts
expressed in HC11-mutB1 versus HC11-FL control cells
(y-axis) and all transcripts expressed in HC11-ΔSAP
versus HC11-FL control cells (x-axis) shows that a large
majority of transcripts does not differ significantly be-
tween the three cell strains (log fold change (FC) ≈ 0;
black dots). Setting the threshold to a 2-fold reduction
(logFC = -1; grey lines), three gene sets can be distin-
guished: 1) blue dots represent genes that are lower in
HC11-mutB1 than in HC11-FL control cells, but are
unaffected in HC11-ΔSAP cells, thus representing typ-
ical SRF/Mkl1 target genes; 2) green dots represent
genes that are lower in HC11-ΔSAP than in HC11-FL
control cells, but are unaffected in HC11-mutB1 cells
(this gene set includes tenascin-C); and 3) red dots indi-
cate genes with reduced expression in both HC11-mutB1
and HC11-ΔSAP cells compared to HC11-FL control cells.
Figure 1 (See legend on next page.)
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Figure 1 Screen for SAP-dependent Mkl1 target genes and their implication in cancer. (A) Scatter plot and (B) Venn diagram representing
classification of Mkl1 target genes into three groups: SRF-dependent/SAP-independent (blue), SRF-dependent/SAP-dependent (red) and
SRF-independent/SAP-dependent (green). The scatter plot (A) represents the log fold change (logFC) in gene expression in HC11-ΔSAP versus
HC11-FL control cells (x-axis; ΔSAP vs. FL) and between HC11-mutB1 versus HC11-FL control cells (y-axis; mutB1 vs. FL). Each dot represents a
probeset, and the one for tenascin-C is highlighted (Tnc). The vertical and horizontal lines in the chart denote the 2-fold change cutoff (logFC
= -1). The Venn diagram (B) represents the number of probesets for transcripts, which are more than 2-fold reduced in either HC11-mutB1 or
HC11-ΔSAP cells when compared to HC11-FL control cells. Boxes below the Venn diagram indicate the cell strains that have reduced levels of
the respective transcripts. (C, D) Functional analysis for the three Mkl1-regulated gene sets performed using the IPA software. The high-level
functional (C) and disease (D) categories are displayed along the x-axis of each bar chart. The y-axis displays the –log of the P-value determined
by right-tailed Fisher’s exact test. The P-value is a measure of the likelihood that the association between a set of genes in each dataset and a
related function or disease is due to random association. The grey vertical line denotes the cutoff for significance (P = 0.05; -logP = 1.3).
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that were distinct from the large majority of transcripts
and were dependent for expression on the B1 site of
Mkl1, the SAP domain, or both. The three groups pre-
sented by a Venn diagram (Figure 1B) contain 141 pro-
besets for transcripts that depended on the function of
the B1 site but not the SAP domain for their induction,
113 probesets for transcripts that depended on both of
these Mkl1 domains and a third group of 205 probesets
for transcripts co-regulated with tenascin-C that did not
require an interaction of Mkl1 with SRF but depended
on the SAP domain for induction (complete probeset
lists and annotations are found in Additional file 1:
Table S1, Additional file 2: Table S2 and Additional file 3:
Table S3). This analysis revealed that the SAP-dependent
mechanism of tenascin-C regulation by Mkl1 is shared
by a large cohort of genes. Below the Venn diagram, we
indicated which cells were deficient in the respective
transcripts. Thus, the typical SRF/Mkl1 target genes are re-
duced in HC11-mutB1 cells, while the SRF-independent/
SAP-dependent genes are reduced in HC11-ΔSAP cells.
The intermediate group that requires both Mkl1 activities
is reduced in both the HC11-mutB1 and HC11-ΔSAP
cells.The SAP-dependent Mkl1 target genes are implicated in
cancer
Functional analysis of the three gene lists using the
IPA software revealed different molecular and cellular
functions (Figure 1C) and different disease associations
(Figure 1D) for the three types of gene signatures. Thus,
the SRF-dependent/SAP-independent signature implicated
a function of these genes in cellular movement and the
linked diseases included connective tissue disorders, in-
flammatory disease and skeletal and muscle disorders,
which are the main features known to be regulated by
SRF/Mkl1 interaction [23-25]. The SRF-dependent/SAP-
dependent group of genes includes as major functions
post-translational modification, protein degradation and
protein synthesis, and the top disease association is cancer.
Finally, the genes of the SRF-independent/SAP-dependentgroup were associated with extremely high significance
with cell cycle and cancer (-logP ≥ 25 and ≥ 30, respect-
ively), while the SRF/Mkl1 target genes were associated
with the same two categories at low significance only
(-logP ≥ 2 and ≥ 7, respectively). These data imply that
SAP-dependent induction of transcription by Mkl1 may
counteract the known differentiation-promoting effect of
SRF/Mkl1-induced transcription. A list of SAP-dependent
genes with published cancer-related functions, whose
transcripts were downregulated more than 3-fold in
HC11-ΔSAP compared to HC11-FL control cells, is pre-
sented in Table 1. To confirm that these transcripts are
indeed differentially expressed in the different HC11
cell strains, qRT-PCR analysis was performed using
cDNA from three different batches of the respective
HC11 strains. Differences in gene expression between
HC11-ΔSAP and control cells are presented in Table 1
and in more detail in Additional file 4: Figure S1. The
qRT-PCR results agreed with the data obtained by tran-
script profiling. We also tested the SAP-dependent gene
expression in the HC11 strains when grown in the pres-
ence of serum. It is interesting to note that in the presence
of 3% FCS, these transcripts remained strongly reduced in
HC11-ΔSAP compared to control cells (Table 1). Thus,
the induction of these genes seems to depend mainly on
whether the SAP domain is present in the transfected
Mkl1 construct.
In addition, we monitored changes in the expression
of some of the SRF-independent/SAP-dependent Mkl1
targets on a protein level. In agreement with the changes
seen at the transcript level, we confirmed the reduction
of tenascin-C, Wisp1 and Nox4 proteins in cells overex-
pressing the ΔSAP-Mkl1 construct compared to the
HC11-FL control and HC11-mutB1 cells (Additional file 4:
Figure S2). Using zymography, we found that Mmp2, a
gene that was not affected by Mkl1 overexpression at
the transcript level was highly expressed in all three cell
strains, whereas Mmp3 and/or 12, which belonged to
the SRF-dependent/SAP-dependent gene set, were al-
most completely lacking in HC11-mutB1 as well as
HC11-ΔSAP cells, corresponding to the data obtained
by transcript profiling.
Table 1 SAP-dependent Mkl1 target genes
Gene Description Fold Reduction in
HC11-ΔSAP vs. HC11-FL cells
Functions
Microarrays
in 0.03% FCS
qRT-PCR in
0.03% FCS
qRT-PCR
in 3% FCS
SRF-independent genes
Tnc Tenascin C, ECM protein 3.07*** 3.50*** 26.34*** Cell adhesion, cell migration, wound healing and tissue
remodeling, cancer cell invasion and metastasis [10]
Anln Anillin, actin binding protein 3.10*** 1.93*** 1.38** Cell cycle regulation [26], cell motility and cancer
progression [26-28]
Nox4 NADPH oxidase 4 3.31*** 94.19** 332.70*** Cell growth, differentiation and migration [29], tumor
angiogenesis [30]
Adamts16 Metallopeptidase, ECM protein 3.63*** 5.70*** 14.84** Cell growth and motility [31], role in arthritis [32] and cancer
[31]
Krt5 Keratin 5, intermediate filament
protein
3.73*** 2.74*** 8.02*** Protein synthesis, epithelial cell growth and
differentiation [33,34]
p15 (PAF) 2810417H13Rik,
PCNA-associated factor
3.91*** 1.89*** 1.34*** DNA repair and cell cycle regulation, cell survival and
proliferation, tumorigenesis [35-37], hematopoiesis [38]
Ass1 Argininosuccinate synthetase 1 4.23*** 3.89** 2.72** Regulation of nitric oxide production and cell viability [39,40]
Cd34 CD34 antigen, stem cell antigen 4.25*** 10.61*** 1.72*** Vessel development and function [41], tumor growth [42,43]
Wisp1 WNT1 inducible signaling
pathway protein 1, ECM protein
4.41*** 2.54** 4.06** Cell proliferation and survival, ECM deposition and turnover,
EMT, tumorigenesis, tissue remodeling [44]
Mcm6 Minichromosome maintenance
complex component 6
4.42*** 2.83*** 1.30*** Cell cycle regulation [45]
Car12 Carbonic anyhydrase 12 4.58*** 16.11*** 26.07** Cell survival under hypoxic conditions, tumor-associated cell
migration and invasion [46,47]
Htatip2 Hyaluronectin, TIP30,
transcriptional regulator
5.89*** 548.59*** 245.27*** Regulation of apoptosis [48], tumor growth and
metastasis [49]
Kif26b Kinesin family member 26B 6.33*** 8.36*** 61.22*** Regulation of adhesion and cell polarity in kidney
development [50]
SRF-dependent genes
Lox Lysyl oxidase, ECM protein 4.61*** 4.70** 12.04*** ECM turnover, connective tissue remodeling and repair,
tumor progression and metastasis [51,52]
Mmp12 Matrix metallopeptidase 12,
metalloelastase
12.01*** 23.49*** 4.90** ECM degradation in tissue remodeling [49] and
tumorigenesis [53]
Mmp3 Matrix metallopeptidase 3,
stromelysin-1
15.64*** 14.70*** 2.08** ECM degradation in tissue remodeling [49] and
tumorigenesis [54]
Abbreviations: ECM extracellular matrix protein, PCNA proliferating cell nuclear antigen, EMT epithelial-to-mesenchymal transition.
***P < 0.001, **P < 0.01, Student’s t test.
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direct Mkl1 target genes
Since we have previously shown that the SAP domain of
Mkl1 interacts with the proximal promoter of tenascin-C
to induce its transcription [13], we tested whether this was
also the case for other transcripts of the same group.
The promoters of the SRF-independent/SAP-dependent
genes listed in Table 1 encompassing at least 500 bp up-
stream of the transcription start site (TSS) were fused
to the secreted alkaline phosphatase (SEAP) reporter
gene of pSEAP2-Basic. We tested the induction of each
promoter-reporter construct by co-transfection with FL-
Mkl1 (Figure 2A). This revealed that the majority of the
new promoters tested (8 out of 12) were induced at least
2-fold by Mkl1 in comparison to co-transfection withan inactive Mkl1 devoid of the transactivation domain,
indicating that these are indeed direct Mkl1 target
genes. The promoter constructs that did not respond to
Mkl1 overexpression may represent genes that are in-
directly regulated by Mkl1, or the relevant promoter
regions were not contained in the constructs tested.
Next, we investigated whether the induction was SAP-
dependent and SRF-independent by comparing the re-
porter activity after co-transfection with mutB1- versus
ΔSAP-Mkl1 variants (Figure 2B). Indeed, the promoter-
reporter constructs induced by FL-Mkl1 were also
strongly induced by mutB1-Mkl1, but not by ΔSAP-Mkl1.
In contrast, the promoter construct for Acta2, a gene from
the SRF-dependent/SAP-independent gene set was strongly
induced by ΔSAP-Mkl1 but not by mutB1-Mkl1, as
Figure 2 SRF-independent/SAP-dependent transcripts represent
direct Mkl1 target genes requiring the SAP domain of Mkl1 to
induce transcription from their proximal promoter. (A) The
indicated promoter constructs that contained at least 500 bp
upstream of the transcription start site (TSS) and were linked to the
secreted alkaline phosphatase (SEAP) reporter gene, were
cotransfected in HC11 cells together with an inactive Mkl1 devoid of
the transactivation domain [13] or the FL-Mkl1 construct. SEAP activity
is expressed as fold induction above the level obtained with the
inactive Mkl1. In addition to Tnc, for 8 out of the 12 new promoters
tested, induction greater than 2-fold (indicated by the red line) was
obtained. Values are means ± SEM from three to seven independent
experiments. (B) HC11 cells were cotransfected with the indicated
promoter constructs that were either > 500 bp or shortened to 200 bp
upstream of the TSS, and with vectors encoding the indicated mutant
Mkl1 constructs. SEAP activity is normalized and expressed as in
(A). Means ± SEM from at least three independent experiments and
significant differences between either mutB1- and ΔSAP-Mkl1-
transactivated promoter constructs or between the longer and shorter
promoter constructs transactivated by mutB1-Mkl1, ***P < 0.001,
**P < 0.01, *P < 0.05 are shown.
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promoters that revealed SAP-dependency were shortened
to 200 bp upstream of the TSS to test whether this was
sufficient to relay the Mkl1 response, as it has been seen
previously for tenascin-C [13]. With the exception of Krt5and Nox4, for which some activity was lost by shortening
the promoters, the 200 bp proximal promoters of all other
genes tested were induced equally well as the longer con-
structs (Figure 2B). Thus, we conclude that there are many
genes that are regulated similarly as tenascin-C requiring
the SAP domain of Mkl1 to induce transcription from
their proximal promoter.
The different HC11 cell strains proliferate at different
rates and show distinct migration behaviors
Next, we tested whether the differential gene expression
seen in the different HC11 strains overexpressing either
FL-, mutB1- or ΔSAP-Mkl1 constructs have functional
consequences on their behavior. Since most of the SAP-
dependent transcripts are proposed to have a function
in cancer, we decided to analyze two main functions im-
portant for cancer progression: proliferation and cell mi-
gration. An approximately equal overexpression of the
different Mkl1 protein variants in the HC11 cell lines was
confirmed by Western blot analysis (Figure 3A). An HC11
cell strain stably transfected with an empty vector [13]
expressing only endogenous Mkl1 (below the detection
limit in Figure 3A) was also included in these studies.
The proliferation rates of the HC11 strains were ana-
lyzed using a 5-bromo-2′-deoxyuridine (BrdU) incorp-
oration assay. The incorporated BrdU was measured
immediately after plating (0 h) as well as at 24, 48, 72
and 96 h. Compared to empty vector-, FL- or mutB1-
transfected HC11 strains, there was a significant decrease
in BrdU uptake into newly synthesized DNA in HC11-
ΔSAP cells over the entire time period tested (Figure 3B).
To investigate cell motility, we used a transfilter migration
assay. Similarly to the effect on cellular proliferation, the
expression of ΔSAP-Mkl1 significantly inhibited HC11 cell
migration by 2.7-fold compared to endogenous or full
length Mkl1 expression, and more than 3.5-fold compared
to mutB1-Mkl1 expression (Figure 3C).
Thus, overexpression of FL-Mkl1 protein in HC11
cells did not affect their behavior. However, overexpres-
sion of ΔSAP-Mkl1 led to a significant reduction in the
proliferative and migratory ability of HC11 epithelial cells,
either through a dominant-negative effect of ΔSAP-Mkl1
on SRF-mediated action and/or a positive impact of the
SAP-dependent Mkl1 target genes on these functions
important for cancer progression.
SAP-dependent Mkl1 target genes are
mechanoresponsive
We have previously found that the SAP-dependent in-
duction of tenascin-C was triggered by applying mech-
anical strain to fibroblasts. Mammary epithelial cells are
also exposed to mechanical strains, both during normal
development, pregnancy and lactation, as well as under
pathological conditions such as in cancer. Therefore, we
Figure 3 The different HC11 cell strains proliferate at different
rates and show distinct migration behaviors. (A) Immunoblot
with mAb65F13 of Mkl1 proteins in whole-cell extracts from the
empty vector-, FL-, mutB1- or ΔSAP-transfected HC11 strains.
Anti-Gapdh served as loading control. Endogenous Mkl1 protein was
below the detection limit in empty vector cells. (B) SAP-dependent
proliferation of HC11 mammary epithelial cells. Proliferation rates of
the four HC11 cell strains were assessed by BrdU incorporation into
newly synthesized DNA immediately after plating (0 h) as well as at
24, 48, 72 and 96 h. Means ± SD from three independent
experiments and significant differences to the HC11-ΔSAP cells,
***P < 0.001, **P < 0.01, *P < 0.05 are shown. (C) SAP-dependent
migration of HC11 mammary epithelial cells. Cell migration of the
four HC11 strains was evaluated by Transwell migration assay using
filters with 8 μm pore size. Quantification of the cell migration was
measured by the area on the lower side of the filter covered with
cells. Above the bar graph, a photo of fixed and stained cells seeded
in parallel in a 24-well plate is shown as a seeding control, and
representative photos of fixed and stained cells of each of the cell
strains that have migrated to the lower side of the filter, are shown
below (bar, 200 μm). Data and statistical significance are expressed
as in (B).
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SAP-dependent Mkl1-induced gene set are mechanore-
sponsive in HC11 cells. We tested two paradigms: 1) static
strain that was shown to induce c-fos, a very prominent
mechanoresponsive gene in HC11 cells [57] that we used
as a control, and 2) cyclic strain. While we were able to
confirm induction of c-fos by applying static strain at 20%
for 1 h, there was no induction of tenascin-C under these
conditions compared to cells at rest (Figure 4A). However,
using 15% cyclic strain at a frequency of 0.3 Hz for 1 h, we
found that not only the control gene c-fos but 11 out of
16 SAP-dependent genes, including tenascin-C were sig-
nificantly upregulated above the expression levels obtained
in resting cells (Figure 4). Even though significant, the in-
duction of tenascin-C was minimal (Figure 4A) compared
to 18-fold upregulation for Adamts16 or 10-fold upreg-
ulation for Lox (Figure 4B), both of which are enzymes
involved in extracellular matrix (ECM) remodeling and
cancer progression [31,58]. Being mechanoresponsive,
the SAP-dependent Mkl1 target genes might be activated
in stiff tumor tissue, which further confirms their relation
with cancer.
The SRF-independent/SAP-dependent genes represent a
bad prognostic signature for breast cancer patients
In order to investigate whether the SRF-independent/SAP-
dependent genes were prognostic of accelerated cancer pro-
gression in human patients, we used the bioinformatics tool
Gene expression-based Outcome for Breast cancer Online
(GOBO) that allowed us to investigate a breast tumor
data set containing 1881 samples analyzed by Affyme-
trix Human Genome U133A arrays. GOBO is designed
to assess gene expression levels and association with out-
come of single genes or gene sets in multiple subgroups of
Figure 4 SAP-dependent Mkl1 target genes are
mechanoresponsive. (A) Effect of static (20%) and cyclic (15%,
0.3 Hz) strain on Tnc and c-fos mRNA levels. HC11 cells were
cultured on either growth factor reduced matrigel matrix- or
fibronectin-coated silicone membranes in 0.03% serum-containing
medium for 24 h before applying static or cyclic strain for 1 h. Cells
cultured under the same conditions and not exposed to mechanical
stimulation were used as a resting control. The two types of coating
gave identical results under the indicated experimental conditions.
Total RNA was extracted and qRT-PCR was performed for Tnc and
c-fos mRNA levels. Values normalized to Gapdh are expressed
relative to the values of resting cells. Data represent means ± SD
from three independent experiments. Significant differences to the
resting control, ***P < 0.001, **P < 0.01, *P < 0.05. (B) SAP-dependent
genes respond to cyclic strain. HC11 cells were stretched and mRNA
analyses were performed as described in (A). Data and statistical
significance are expressed as in (A).
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sets of genes, namely the SRF/Mkl1-induced gene set
(SRF-dependent/SAP-independent) and the SAP-dependent
gene set (SRF-independent/SAP-dependent) containing
tenascin-C. The analysis was performed across tumor
samples stratified according to PAM50 subtypes [60],
estrogen receptor (ER)-status and histological grade. In
contrast to the SRF/Mkl1 target genes that were predom-
inantly associated with tumors classified as normal-likeand with lower histological grades (1 and 2) (Figure 5A),
elevated expression of SAP-dependent genes was associ-
ated with extremely high significance (P < 0.00001) with
typical high-proliferative poor outcome classes in breast
cancer, such as basal-like, HER2-enriched, luminal B, ER-
negative and histological grade 3 tumors (Figure 5B). Next,
a functional correlation analysis to find a possible inter-
connection between the SAP-dependent Mkl1 target
genes was performed using the GOBO tool (Additional
file 4: Figure S3). This analysis explores the correlation
of expression of individual genes in our gene sets with
eight different co-expressed gene modules emulating
breast cancer-specific as well as general tumor biological
processes [61]. Interestingly, whereas the gene set of SRF/
Mkl1 targets did not show a significant correlation with
any of these modules, the genes in the SAP-dependent
gene set were correlated with a very high significance
(P < 0.00001) with two proliferation modules – mitotic
checkpoint and mitotic progression. Both modules con-
tain genes related to central mitotic processes involved
in either the regulation of the M-phase and the mitotic
checkpoint or in carrying out the M-phase. Finally, the
association of our gene sets with outcome using distant
metastasis free survival (DMFS) as an endpoint and 10-
year censoring was analyzed. The survival analysis was
performed in all tumors for which DMFS follow-up is
available (1379 cases), as well as in 21 groups that were
stratified based on gene expression subtypes (PAM50
classifier), ER-status, lymph node (LN)-status, histological
grade, and treatment status. Samples in the whole cancer
data set (1881 patients) were stratified into three quan-
tiles, low, intermediate and high, based on SRF-dependent/
SAP-independent or SRF-independent/SAP-dependent gene
expression. Interestingly, high expression of SRF/Mkl1-
induced genes was associated with a better clinical out-
come for all tumors, as well as for LN-negative and
untreated tumors compared to low and intermediate ex-
pression of these genes (Figure 6A). In contrast, both high
and intermediate expression of the SAP-dependent genes
was associated with bad clinical outcome in all tumors,
and particularly in LN-negative, systemically untreated,
ER-positive, Grade 1 and 2 tumors (Figure 6B). Similar re-
sults were obtained for the typical breast cancer gene
CCNB1 by Ringnér et al. [59]. The Kaplan-Meier survival
analyses were supported by the corresponding multivariate
analyses (Figure 7A, B). The hazard ratio for the variate
Grade shows statistical significance, proving that the in-
fluence of high SAP-dependent gene expression on pa-
tient survival is independent of tumor grade. Among all
tumors for which DMFS data are available, a hazard ra-
tio of 0.44 (95% CI = 0.28-0.68; P = 0.0003) for the low
SRF-independent/SAP-dependent tercile was detected
compared to the high SRF-independent/SAP-dependent
tercile (Figure 7B, all tumors). This indicates that patients
Figure 5 SAP-dependent Mkl1 target genes are associated with typical high-proliferative poor outcome classes in breast cancer. The
expression levels for the SRF-dependent/SAP-independent (A) and SRF-independent/SAP-dependent (B) gene sets are analyzed across the
1881-sample breast cancer data set stratified according to PAM50 subtypes (left panels), estrogen receptor (ER)-status (middle panels) and
histological grade (right panels), and represented by box plots using the GOBO bioinformatics tool. The number of tumors in each breast cancer
subtype and the significant difference in gene expression (P-value calculated using ANOVA) between them are shown above the box plots.
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genes are more than twice as likely to develop metastatic
disease. Similar hazard ratios, in the range of 0.28-0.44
for the low tercile compared to the high tercile were also
detected among subgroups of untreated, LN-negative,
ER-positive, Grade 1 and 2 tumors (Figure 7B). Thus,
the association of high SRF-independent/SAP-dependent
gene expression with reduced DMFS among patients not
receiving adjuvant therapy, as well as among LN-negative,
ER-positive, Grade 1 and 2 patients indicates that in-
creased expression of the SAP-dependent Mkl1 target
genes plays a significant role in the natural metastatic
progression of non-aggressive towards highly aggressive
breast cancer in human patients.Discussion
Given the heterogeneity of mutations in tumor cells, it
becomes increasingly clear that not only individual
genes but pathways govern the course of tumorigenesis
and cancer progression [62]. We have recently shown
that induction of tenascin-C by cyclic mechanical strain
required the action of the potential DNA-binding SAP
domain of Mkl1 independently of an interaction of
Mkl1 with SRF [13]. Now, we report a screen for genes
co-regulated with tenascin-C by the same SAP-dependent
and SRF-independent mechanism in mammary epithelial
cells. This screen reveals a set of SAP domain-dependentMkl1 target genes with a strong implication in cell prolif-
eration, cell motility and cancer.
To date only a few studies have shown that Mkl1 is
implicated in cancer-related processes (reviewed in [63])
and most of them have concentrated on the SRF/Mkl1
signaling for the induction of individual genes [64-67].
The first study reporting that depletion of Mkl1/2 proteins
reduced motility, invasion and colonization of metastatic
tumor cells in an experimental in vivo metastasis assay
[64] was further supported by the discovery of the Mkl1-
binding protein, suppressor of cancer cell invasion (SCAI),
which inhibited SRF/Mkl1-mediated expression of β1 in-
tegrin [68]. Since then, several studies describing opposing
biological effects for Mkl1 appeared. For instance, several
antiproliferative SRF/Mkl1 target genes including mig6/
errfi-1, a negative regulator of the EGFR-MAPK pathway,
were identified [65], or the tumor suppressor gene Eplin-α
was described as a direct target of the SRF/Mkl1 path-
way [66]. Furthermore, expression of a constitutively ac-
tive form of Mkl1 in oncogenic ras- or src-transformed
rat intestinal epithelial cells injected into the spleen of
nude mice significantly suppressed tumor formation
and reduced liver metastases by rescuing the expression
of the SRF/Mkl1 targets tropomyosin and caldesmon
[67]. In line with these findings, we could show that
high expression of SRF/Mkl1 target genes is associated
with an improved clinical outcome in breast cancer pa-
tients. However, the opposite is the case for high expression
Figure 6 The SRF-independent/SAP-dependent genes represent a bad prognostic signature for breast cancer patients. Tumors in the
1881-sample breast cancer data set were stratified into three quantiles, low, intermediate and high, based on SRF-dependent/SAP-independent
(A) or SRF-independent/SAP-dependent (B) gene expression. (A) Kaplan-Meier survival analysis using distant metastasis free survival (DMFS) as endpoint
and 10-year censoring for all tumors (n = 1379; left panels), or in the subgroups of lymph node (LN)-negative (n = 1111; middle panels) and untreated
tumors (n = 821; right panels) was performed using the GOBO bioinformatics tool, interrogating the group of SRF-dependent/SAP-independent target
genes. P-value is calculated using log-rank test. (B) Kaplan-Meier survival analysis for tumors with expression of SRF-independent/SAP-dependent Mkl1
target genes was performed as in (A). Association with clinical outcome was assessed in the subgroups of ER-positive (n = 856; left panel),
Grade 1 (n = 141, middle panel) and Grade 2 (n = 446; right panel) tumors in addition to all tumors and the subgroups used in (A). P-value is
calculated using log-rank test.
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ciated with poor clinical outcome predominantly in less ag-
gressive tumors such as LN-negative, ER-positive, Grade 1
and 2 tumors, which makes them valuable predictors of
breast cancer progression. A scheme that depicts our modelfor Mkl1 action in breast cancer is presented in Figure 8. In
this model Mkl1 is transactivating SRF-target genes in less
aggressive tumors, while in the course of cancer progres-
sion and metastatic behavior Mkl1 is activating a new
group of genes in a SAP-dependent manner either by direct
Figure 7 Elevated expression of SAP-dependent Mkl1 target genes is a poor prognosis factor in breast cancer independent of histological
grade. Multivariate analysis supporting the Kaplan-Maier survival analysis (shown in Figure 6) for the SRF-dependent/SAP-independent (A) and
SRF-independent/SAP-dependent (B) gene sets, was performed using the GOBO bioinformatics tool. The analysis was executed for all tumors
(n = 1379) and in the subgroups of LN-negative (n = 1111) and untreated tumors (n = 821) (A, B), as well as in the subgroups of ER-positive
(n = 856), Grade 1 (n = 141) and Grade 2 (n = 446) tumors (B), using LN-status, ER-status, and stratified histological grade (histological grade 1
and 2 vs. 3) as covariates, DMFS as endpoint and 10-year censoring. The hazard ratio and the 95% confidence interval (CI) are plotted for each
of these covariates. Specified covariates may be omitted in certain comparisons, e.g. ER-status is omitted when analyzing ER-positive tumors
only, or when not all of the investigated cases have clinical follow-up or clinical information for the specified covariate.
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action with additional DNA-binding factors.
Interestingly, in parental HC11 cells many of the genes
that we found in the SAP-dependent gene set that foster
cell proliferation and migration and may cause poor
survival of breast cancer patients are also induced by
mechanical strain. A recent study has demonstrated
that inhibition of cell spreading due to a lack of matrix
stiffness is overcome by externally applied stretch, sug-
gesting that similar mechanotransduction mechanisms
sense stiffness and stretch [69]. Tumor stroma is typically
stiffer than normal stroma. In breast cancer, diseased tis-
sue can be 10 times stiffer than normal breast [70,71]. It is
known that abnormal ECM stiffness plays an important
role in cancer progression [72,73], but the mechanisms by
which stiffness influences cancer progression are still
under investigation. If we assume that we have discovered
a general reaction of mammary epithelial cells to mechan-
ical strain, we envisage that epithelial cells in a stiff,mechanically dynamic tumor environment may react by
inducing a SAP-dependent Mkl1 gene set that in turn
affects tumor progression. Furthermore, the products of
these genes, many of which are involved in ECM turn-
over and function, for example Lox [58], Mmps [74],
Adamts16 [31] or Wisp1 [44] might themselves manipu-
late the tumor microenvironment, thereby influencing
tumor cell survival by a positive tumorigenic feedback
loop.
Finding how to switch the mode of action of Mkl1 be-
tween SRF transactivation versus its SAP-dependent
transcriptional activity is a subject of ongoing research
in our lab that in future may help with the development
of new therapeutic interventions for breast cancer. Post-
translational modifications such as sumoylation are known
to influence Mkl1 transcriptional activity [75] and phos-
phorylation has been shown to influence interaction of
Mkl1 with nuclear actin resulting in transcriptional
changes [76,77]. Further characterization of these and
Figure 8 Schematic representation of the Mkl1 action in breast cancer. A circular Mkl1 model is depicted with four of its domains: RPEL,
actin binding motifs with RPxxxEL core consensus; B1, basic domain involved in SRF-binding; SAP, homology domain found in the nuclear
proteins SAF-A/B, Acinus, PIAS; TAD, transactivation domain. Serum response factor is drawn as a red shape and putative unidentified
DNA-binding proteins as white shape with a question mark. Mkl1 exerts two distinct modes of action: one of them is through the B1 domain
required for serum response factor (SRF)-binding activity and induction of SRF/Mkl1 target gene expression; the other one is strongly dependent
on the SAP domain and triggers the expression of a specific set of pro-proliferative and pro-migratory genes that we called SAP-dependent Mkl1
target genes. High expression of SRF-dependent genes is associated with good clinical outcome for breast cancer patients, whereas elevated
expression of SAP-dependent targets correlates with poor prognosis and indicates a significant role for these genes in breast cancer progression.
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cial attention when trying to answer the above question.
Conclusions
In the current study, we discovered a breast cancer-
specific set of genes that is highly interesting as a prog-
nostic marker and therapeutic target for several reasons.
(1) The expression of this gene set is regulated by Mkl1
and its SAP domain and is independent of SRF. (2) The
SAP-dependent, SRF-independent Mkl1signaling is trig-
gered by mechanical strain and may thus be activated in
stiff tumors with a high stromal content and high inter-
stitial tissue pressure. (3) This gene set is composed of
interesting members some of which represent novel
candidates for playing a functional role in cancer and
others that have already been implicated in cancer-
related functions, as for example tenascin-C, a meta-
static niche component important for lung colonization
[8], or Lox as a gene mediating collagen crosslinking re-
sponsible for fibrosis-enhanced metastasis [58]. (4) The
SAP-dependent Mkl1 target genes are associated with a
poor clinical outcome in breast cancer patients, not re-
ceiving adjuvant therapy or having a cancer classified
as non-aggressive such as LN-negative, ER-positive,
Grade 1 or 2 tumors. This makes these genes potential
valuable prognostic markers in selecting patients whomay benefit from an immediate and/or more aggressive
therapy.
Methods
Cell culture
Full length Mkl1 (FL-Mkl1) and the two Mkl1 mutants,
mutB1-Mkl1 comprising alanine substitutions of four
amino acids (underlined) in the B1 domain of Mkl1 (KKA
KELKPKVKKLKYHQYIPPDQKQD) [78] and ΔSAP-Mkl1
with a deletion of the SAP domain [15], were constructed
based on transcript variant 1 (GenBank accession num-
ber NM_153049) as previously described [13]. All Mkl1
variants were expressed as C-terminal RFP-tagged fusions.
An empty vector expressing RFP alone was previously
described [13].
HC11 mammary epithelial cells, kindly provided by
Dr. N. Hynes (Basel, Switzerland), were grown in RPMI-
1640 medium supplemented with 10% FCS, 5 μg/ml insu-
lin (Sigma, Buchs, Switzerland) and 10 ng/ml epidermal
growth factor (EGF; Invitrogen, Zug, Switzerland). In most
of the experiments, the HC11 cells were starved in 0.03%
FCS/RPMI without EGF. To obtain HC11 cells stably
expressing FL-Mkl1-RFP (HC11-FL), mutB1-Mkl1-RFP
(HC11-mutB1), ΔSAP-Mkl1-RFP (HC11-ΔSAP) or RFP
alone (HC11-empty vector), cells were transfected using
FuGENE® 6 (Roche, Basel, Switzerland) and selected
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fluorescence-activated cell sorting (FACS) of RFP-positive
cells on aVantage SE (Becton Dickinson, Basel, Switzerland).
Cell viability of the four HC11 cell strains was assessed by
the CellTiter-Blue viability assay (Promega, Duebendorf,
Switzerland).
Cell proliferation assay
Proliferation rates of the HC11 cell strains were determined
using BrdU incorporation assay (Roche). After 24 h of star-
vation, cells were plated in triplicate on Black 96-well mi-
crotiter plates (PerkinElmer, Schwerzenbach, Switzerland)
at 5 × 103 cells/well in 3% FCS/RPMI and allowed to pro-
liferate for 0, 24, 48, 72 and 96 h before labeling with BrdU
for 2 h. BrdU incorporation into newly synthesized DNA
was determined according to the manufacturer’s protocol
using a Luminometer Mithras LB940 (Berthold Technolo-
gies, Regensdorf, Switzerland). Experimental values were
normalized to the values of HC11-ΔSAP cells at the time
point 0. Data represent means ± SD from three independ-
ent experiments.
Cell migration assay
Cell migration was assayed using transwell polycarbonate
membrane inserts (6.5 mm; Corning, Amsterdam, The
Netherlands) with 8 μm pores as described [79]. After
24 h of starvation, 5 × 104 cells were plated in the top in-
sert chamber with 100 μl serum-free RPMI. The lower
chamber was filled with 600 μl 10% FCS/RPMI. Cells were
allowed to migrate across the filter for 22 h at 37°C before
fixation and crystal violet-staining. Images of duplicate in-
serts were acquired on a Nikon Eclipse E600 using 10×
magnification and a color CCD camera. Migration was
quantified by measuring the area covered by migrated cells
using the Fiji distribution of ImageJ [80]. Data represent
means ± SD from three independent experiments.
Mechanical stimulation of cells
2 × 105 HC11 cells/well were seeded in BioFlex® 6-well
culture plates (Flexcell International, Hillsborough, NC,
USA) coated with either growth factor reduced-Matrigel
(BD Biosciences, Basel, Switzerland) or fibronectin [11].
Cultures were starved for 24 h before applying either
equibiaxial cyclic strain (15%, 0.3 Hz) or static strain
(20%) at 37°C for 1 h using Flexcell FX-4000 (Flexcell
International). Cells cultured under the same conditions
and not exposed to strain were used as a resting control.
After mechanical stimulation, cells were lysed and total
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Basel, Switzerland).
Transcript profiling and bioinformatics analysis
HC11 cell strains stably expressing Mkl1 variants were
starved for 48 h before total RNA was extracted,converted into labeled cDNA and hybridized to Affy-
metrix GeneChip Mouse Gene 1.0 ST arrays. RMA-
normalized expression values were calculated with the
Affy package from Bioconductor 2.4 [81], and differen-
tially expressed genes were identified using moderated
t-statistics calculated with the empirical Bayes method
as implemented in the Bioconductor limma package
[82]. To be considered as differentially expressed be-
tween HC11-FL and HC11-mutB1 or HC11-ΔSAP
cells, genes had to pass the filters: adjusted P-value ≤
0.01 (with Benjamin-Hochberg false discovery correc-
tion), a minimum absolute linear fold change differ-
ence of 2.0 and a minimum average expression value of
4.0 (log2). Microarray data files are available from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/), accession number GSE44907. Using the
above parameters, gene lists of the two contrasts (mutB1/
FL and ΔSAP/FL) were compared resulting in the forma-
tion of three gene groups: SRF-dependent/SAP-independ-
ent, SRF-dependent/SAP-dependent and SRF-independent/
SAP-dependent. The three gene sets were analyzed using
the bioinformatics softwares: 1) IPA (Ingenuity® Systems;
www.ingenuity.com); and 2) GOBO (http://co.bmc.lu.se/
gobo) [59]. In order to use the latter tool, Affymetrix Gene-
Chip Mouse Gene 1.0 ST IDs were mapped to Affymetrix
Human Genome U133A IDs using Biomart for Ensembl
build 66. The module “Gene Set Analysis Tumors” was
used to investigate the expression pattern and to per-
form survival and functional correlation analyses for the
SRF-dependent/SAP-independent and SRF-independent/
SAP-dependent gene sets across 1881 breast cancers char-
acterized by Affymetrix Human Genome U133A arrays.RNA analyses by qRT-PCR
Total RNA was isolated from HC11 cell strains after
24 h of incubation either in 0.03 or 3% FCS/RPMI.
RNA was reverse transcribed and relative tenascin-C
and c-fos mRNA levels were detected as described
[12,13]. Relative mRNA levels for the genes listed in
Table 1, normalized to Gapdh, were measured using
Platinum® SYBR® Green qPCR SuperMix-UDG with
ROX (Invitrogen) and the primers listed in Additional
file 4: Table S4. Real-time PCR was performed in a Ste-
pOnePlus Real-Time PCR System (Applied Biosystems,
Rotkreuz, Switzerland) using a standard cycling profile.
All samples were run in duplicate. Data were analyzed
by the ΔCt method [83] and presented as fold changes
in mRNA expression levels between HC11-FL and
HC11-ΔSAP cells. RNA from stretched cells was ana-
lyzed by qRT-PCR using the efficiency ΔΔCt method
[84] that included a further normalization to the rest-
ing control. Data represent means ± SD from three in-
dependent experiments.
Gurbuz et al. Molecular Cancer 2014, 13:22 Page 14 of 16
http://www.molecular-cancer.com/content/13/1/22Protein analyses by immunoblotting and zymography
After 24 h of starvation, whole-cell extracts from the
three HC11 strains were prepared in RIPA buffer and
immunoblotting was performed as described [12,13].
The following primary antibodies were used: mAb65F13
anti-Mkl1 [12], MTn12 anti-Tnc [85], anti-Wisp1/CCN4
(clone 214203, R&D Systems), anti-Nox4 (NB110-58851,
Novus Biologicals), anti-Vcl (clone hVIN-1, Sigma) and
anti-Gapdh (ab9485, Abcam).
After reaching 90% confluency, HC11 strains were
starved for 48 h before conditioned medium was col-
lected, concentrated and analyzed by zymography as
described [86].Promoter-reporter assays
The tenascin-C promoter used in this study was described
as TNC 247 bp [13]. Promoters of Acta2 [87] and all SRF-
independent/SAP-dependent genes described in Table 1
were PCR-amplified from genomic DNA and corresponded
to the sequences listed in Additional file 4: Table S5. Each
promoter contained ≥ 500 bp 5′ of the TSS and was cloned
into the pSEAP2-Basic (Clontech, Saint-Germain-en-Laye,
France). For some promoters also 200 bp proximal pro-
moter sequences were cloned as described above. All clones
were verified by DNA sequencing.
HC11 cells in 6-well plates were cotransfected with
1 μg of the SEAP reporter vectors, 1 μg of pcDNA3 vectors
encoding Mkl1 variants [13], and 200 ng of the secreted
luciferase MetLuc vector (Clontech) used to normalize
for transfection efficiency. Cells were cultured in 0.03%
FCS/RPMI for 24 h before enzymatic activity measure-
ments were performed as described [13]. Experimental
values represent averages of three independent experi-
ments, each performed in duplicate.Statistical analysis
Numerical results were expressed as means ± SD. Stat-
istical analysis was completed using GraphPad InStat
Software, version 3.05. The two-tailed Student’s t test
was used to evaluate differences between two groups.
Multiple comparisons were performed using one-way
analysis of variance (ANOVA). Values of P less than 0.05
were considered statistically significant. Statistics for bio-
informatics analyses is given in figure legends.Additional files
Additional file 1: Table S1. SRF-dependent/SAP-independent
probeset list.
Additional file 2: Table S2. SRF-dependent/SAP-dependent probeset
list.
Additional file 3: Table S3. SRF-independent/SAP-dependent
probeset list.Additional file 4: Table S4. Primer sequences. Table S5. Promoter
constructs. Figure S1. Quantification of SAP-dependent Mkl1 target gene
expression using qRT-PCR analysis. Figure S2. Differential expression of
newly discovered Mkl1 target genes in HC11 strains overexpressing either
FL-, mutB1- or ΔSAP-Mkl1 constructs (protein analyses performed by
immunoblotting and zymography). Figure S3. SAP-dependent Mkl1
target genes are correlated with a very high significance (P < 0.00001)
with the two proliferation modules – mitotic checkpoint and mitotic
progression (a functional correlation analysis performed using the GOBO
bioinformatics tool).
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2.1.1 Supplementary information 
 
Additional file for: 
 
“SAP domain-dependent Mkl1 signaling stimulates proliferation and cell 
migration by induction of a distinct gene set indicative of poor prognosis in 
breast cancer patients”  
 
Content: 
Table S4. Primer sequences. 
Table S5. Promoter constructs. 
Figure S1. Quantification of SAP-dependent Mkl1 target gene expression 
using qRT-PCR analysis. 
Figure S2. Differential expression of newly discovered Mkl1 target genes in 
HC11 strains overexpressing either FL-, mutB1- or ΔSAP-Mkl1 constructs 
(protein analyses performed by immunoblotting and zymography). 
Figure S3. SAP-dependent Mkl1 target genes are correlated with a very high 
significance (P < 0.00001) with the two proliferation modules: mitotic 
checkpoint and mitotic progression (a functional correlation analysis 
performed using the GOBO bioinformatics tool). 
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Table S4. Primer Sequences. 
Gene 
symbol 
Gene bank accession 
number 
          Primer pair (fwd/rev) Amplicon 
size (bp) 
Anln NM_028390.3 5’-CAGTGGTGACGCTCTGACAT-3' 
5’-GGGACTGGCCATAACTGAAG-3' 
220 
Nox4 NM_015760.4 5’-CATTCCAGTGGTTTGCAGATT-3' 
5’-AACTGGGTCCACAGCAGAAA-3' 
249 
Adamts16 NM_172053.2 5’-TTGGAGAGAAAGCCAAGCTC-3' 
5’-GGGCCTTCATCACCGTACT-3' 
181 
Krt5 NM_027011.2 5’-CAGGACCTGGTGGAGGACTA-3' 
5’-CCATGGAAAGGACCACAGAT-3' 
241 
p15(PAF) NM_026515.2 5’-GGGAATTCTTCAGGCTGTCC-3' 
5’-CAACAAGCCAATTGGACAAA-3' 
227 
Ass1 NM_007494.3 5’-CACCACATCCCTGGAACTCT-3' 
5’-ATGAGCGTGGTAAAGGATGG-3' 
151 
Cd34 NM_001111059.1 5’-AGGCTGATGCTGGTGCTAGT-3' 
5’-ACTCCAGAGGTGACCAATGC-3' 
235 
Wisp1 NM_018865.2 5’-GCTCTACCACCTGTGGCCTA-3' 
5’-ACAGCCTGCGAGAGTGAAGT-3' 
194 
Mcm6 NM_008567.1 5’-CATGTCCCGCTTTGATCTCT-3' 
5’-CTGGCGGAGACGTTTGTACT-3' 
232 
Car12 NM_178396.4 5’-GTTCGATGAGAGGCTGGTGT-3' 
5’-CCTCAGCCTCCTTCTTGATG-3' 
215 
Htatip2 NM_016865.3 5’-GCTGGATGTCTATGCTTCTGC-3' 
5’-TCAACCTTGGCTTCCACTTC-3' 
243 
Kif26b NM_001161665.1 5’-AAGAAGCAGCCAGGTTCCTC-3' 
5’-AATGCCCAGGTTCTGCATAG-3' 
214 
Lox NM_010728.2 5’-CAGGGATTGAGTCCTGGATG-3' 
5’-ACTGGGAACTGGGCTTCTTT-3' 
242 
Mmp12 NM_008605.3 5’-CATCCCATCTGGTATTCAAGC-3' 
5’-ATGAGCTCCTGCCTCACATC-3' 
249 
Mmp3 NM_010809.1 5’-CATCACCAATGTGCAGCTCT-3' 
5’-CTCCTCGTGCCCTCGTATAG-3' 
248 
Gapdh NM_008084.2 5’-CTTGTGCAGTGCCAGCCTC-3' 
5’-GCCGTGAGTGGAGTCATACTG-3' 
189 
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Table S5. Promoter constructs. 
Promoter Accession number Nucleotide position 
mTNC 247bp NT_039260.7 3336826-3336433 
Wisp1 >500bp NT_039621.7 28008443-28009129 
Wisp1 200bp NT_039621.7 28008801-28009129 
Krt5 >500bp NT_039621.7 62829844-62829249 
Krt5 200bp NT_039621.7 62829551-62829249 
Kif26b >500bp NT_039185.7 22360019-22360523 
Kif26b 200bp NT_039185.7 22360158-22360523 
Htatip2 >500bp NT_039424.7 10657737-10658750 
Htatip2 200bp NT_039424.7 10658493-10658750 
Nox4 >500bp NT_039433.7 4994940-4995484 
Nox4 200bp NT_039433.7 4995123-4995484 
Car12 >500bp NT_039474.7 12981551-12982239 
Car12 200bp NT_039474.7 12981860-12982239 
Adamts16 >500bp NT_039589.7 16522290-16521672 
Adamts16 200bp NT_039589.7 16522032-16521672 
Cd34  >500bp NT_039190.7 2888907-2889501 
Cd34  343bp NT_039190.7 2889159-2889501 
Anln >500bp NT_039472.7 8976459-8975867 
p15(PAF) >500bp NT_039474.7 12158197-12158785 
Mcm6  >500bp NT_078297.6 42913044-42912468 
Ass1 >500bp NT_039206.7 8927941-8928521 
Acta2 562bp NT_039687.7 27442283-27441676 	
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Figure S1. Quantification of SAP-dependent Mkl1 target gene expression using qRT-
PCR analysis. Relative mRNA levels for the genes listed in Table 1, normalized to Gapdh, 
were analyzed in HC11 cells stably transfected with either empty vector or with vectors 
encoding FL-, mutB1- or ΔSAP-Mkl1 proteins. The results agreed with the data obtained by 
transcript profiling (Figure 1). Induction of these genes strongly depends on the SAP domain 
of Mkl1 as well as on the B1 domain for Lox, Mmp12 and Mmp3 genes, which belong to the 
SRF-dependent/SAP-dependent gene set. Means ± SD from three independent experiments 
and significant differences to the HC11-FL cells, ***P < 0.001, **P < 0.01, *P < 0.05 are 
shown. 
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Figure S2. Differential expression of newly discovered Mkl1 target genes in HC11 
strains overexpressing either FL-, mutB1- or ΔSAP-Mkl1 constructs. Western blot 
analysis of Tnc, Wisp1 and Nox4, and zymographic analysis for Mmp12/3 show SAP-
dependent protein expression in HC11 epithelial cells. Secreted Tnc protein was detected in 
cell culture media using the MTn12 anti-Tnc antibody, and bovine serum albumin (BSA) from 
the medium visualized by Ponceau S staining served as loading control. Wisp1 and Nox4 
proteins were detected in whole-cell extracts from the three HC11 cell strains, HC11-FL, 
HC11-mutB1 and HC11-ΔSAP using respective antibodies. Anti-Vcl served as loading 
control. Conditioned media from the three HC11 cell strains was subjected to casein or 
gelatin zymography for detection of the matrix metalloproteinases Mmp12/3 and Mmp2, 
respectively. For Mmp2, both an inactive (proMmp2) and active form was detected and 
served as loading control. Relevant bands and molecular weight markers (in kDa) are 
indicated on the right and left of each panel, respectively. 
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Figure S3. SAP-dependent Mkl1 target genes are correlated with a very high 
significance (P < 0.00001) with the two proliferation modules – mitotic checkpoint and 
mitotic progression. Functional correlation of genes in the SRF-dependent/SAP-
independent (left panel) and SRF-independent/SAP-dependent (right panel) gene sets to 
different gene expression modules emulating breast cancer-specific biological processes [33] 
was performed using the GOBO bioinformatics tool. For each gene module and gene in the 
two gene data sets, a Spearman correlation value is computed by comparing the expression 
pattern across all samples for a specific gene to the corresponding rank sum for each sample 
in the specific module. Dots indicate actual correlation values. 
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2.2 Unpublished Results 
 
2.2.1 WISP1 mRNA expression in transformed mouse mammary 
epithelial cell lines 
Isogenic mouse breast cancer cell lines, 67NR, 168FARN, 4T07, 4T1 can 
form primary tumors with equivalent kinetics but differ in their ability to 
metastasize when implanted into the mammary glands of BALB/c mice 
(Aslakson and Miller, 1992) (Figure 1). 67NR cells can form primary tumors, 
but tumor cells do not intravasate and metastasize. 168FARN cells are slightly 
metastatic and can be detected in the lymph nodes, but rarely in other tissues 
such as the lungs. This observation suggest that 168FARN cells can 
disseminate from the primary tumor site and enter the blood stream, however 
they do not extravasate efficiently.  Cells of the 4TO7 line are able to spread 
to the lungs, but cannot form visible metastatic nodules. Moreover, when the 
primary 4T07 tumor is removed, clonogenic cells within the lungs disappear 
suggesting that they fail to colonize distant sites. 4T1 cells are fully metastatic 
and can form macroscopic lung nodules (Aslakson and Miller, 1992). 
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Figure 1: The breast cancer metastasis model comprising four isogenic mouse mammary 
tumor cell lines that differ in their ability to metastasize when implanted into the mammary fat 
pad. (Schematic representations were adapted from Yang et al., 2004 and Ho et al., 2009). 
We analyzed the endogenous WISP1 mRNA levels in the parental isogenic 
tumor cells, 67NR, 168FARN, 4T07 and 4T1. Compared with the non-
metastatic 67NR cells, 168FARN and 4T07 cells exhibit ~6 fold higher WISP1 
mRNA expression. Strikingly, WISP1 mRNA levels in the aggressively 
metastatic 4T1 cells were ~18 fold higher compared with 67NR cells. This 
result shows that the endogenous WISP1 levels correlate with the metastatic 
potential of mouse mammary tumor cell lines (Figure 2).  
 
 
 
Figure 2: qRT-PCR analysis of 
WISP1 mRNA expression in isogenic 
mouse mammary epithelial tumor cell 
lines with different metastatic 
potential. WISP1 mRNA levels in all 
cell lines were normalized towards 
WISP1 mRNA levels in 67NR cells. 
Data represent means ± SD from 
technical replicates 
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2.2.2 Change in WISP1 mRNA expression in response to WNT ligand 
Wnt3A stimulation 
The normal mouse mammary epithelial cell line HC11 is derived from 
COMMA-1D mouse mammary epithelial cells that were isolated from 
mammary tissue of mid-pregnancy Balb/c mice (Danielson et al., 1984; Ball et 
al., 1988). HC11 cells resemble mammary stem cells or progenitor cells and 
possess unlimited proliferation capacity. They are able to differentiate into 
milk-producing cells in vitro  (Ball et al., 1988) and to reconstitute the ductal 
epithelium of a cleared mammary fat pad with myoepithelial, alveolar and 
ductal luminal cells in vivo (Humphreys et al., 1997).  
 
WISP1 is a downstream target of the canonical WNT/β-catenin signaling 
pathway (Pennica et al., 1998; Xu et al., 2000). Hence, stimuli activating the 
WNT/β-catenin signaling pathway are expected to increase the expression of 
the target genes, including WISP1. Activation of WNT/β-catenin signaling is 
linked to different pathologies including fibrosis and cancer (Clevers 2006; 
Konigshoff et al., 2009). Previously, Konigshoff and colleagues have shown 
that either the treatment of mice with the recombinant Wnt3A or induction of 
experimental lung fibrosis in mice result in WNT/β-catenin pathway activation 
(Konigshoff et al., 2009). Furthermore, they reported that WISP1 expression 
in primary alveolar epithelial type II (ATII) cells increases upon Wnt3A 
stimulation in vitro (Konigshoff et al., 2009). 
 
To test whether activation of WNT/β-catenin signaling results in upregulation 
of WISP1 in mouse mammary epithelial cells, we stimulated the cells with 
WNT ligand Wnt3A for 12 and 24 hours. For Wnt3A stimulation, cell culture 
media of L cells stably overexpressing Wnt3A was used. The presence of 
Wnt3A protein was confirmed by immunoblotting (Figure 3A). As seen in 
figure 3B, compared to untreated control cells, WISP1 mRNA levels in HC11 
normal mouse mammary epithelial cells stimulated with Wnt3A didn’t 
increase. On the contrary, we observed a slight decrease of WISP1 
expression in HC11 cells in response to Wnt3A treatment. However, WISP1 
expression in mouse mammary tumor cells did increase upon Wnt3A 
treatment. In 168FARN cells the change in WISP1 mRNA levels after both 12 
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hours and 24 hours treatment was minor. WISP1 expression in 67NR, 4T07 
and 4T1 cells slightly increased after 12 hours of Wnt3A stimulation (less than 
1.5 fold). The upregulation of WISP1 expression was more prominent after 24 
hours of Wnt3A treatment (1.5 fold for 67NR cells, more than 2 fold for 4T07 
cells and 2 fold for 4T1 cells). Thus, although we could not observe activation 
of WNT/β-catenin signaling and subsequent upregulation of the target gene 
WISP1 in normal mammary epithelial cells, most of the mammary tumor cells 
(3 out of 4) responded to WNT ligand treatment by increased WISP1 
expression.  
 
 
 
Figure 3: Change in WISP1 mRNA expression in response to WNT ligand Wnt3A stimulation. 
A) Immunoblot with anti-Wnt3A antibody of Wnt3A in L Wnt3A cell culture medium and 
control cell medium. Samples were run on a 10 % SDS-PAGE gel. B) Change in WISP1 
mRNA expression in response to Wnt3A treatment for 12 hours and 24 hours. mRNA 
expression levels were normalized towards the WISP1 mRNA expression in untreated cells. 
Data represent means ± SD from technical replicates.  
 
2.2.3 WISP1 mRNA expression in tumors growing in pre-irradiated 
stroma versus non-irradiated control stroma  
It was previously shown that the expression of CYR61/CCN1, another CCN 
family member is elevated in cell lines derived from subcutaneous tumors 
grown in irradiated mice compared with the cell lines derived from tumors 
grown in non-irradiated mice (Monnier et al., 2008). In an orthotopic breast 
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cancer model tumors growing in pre-irradiated mammary tissue were more 
invasive compared with control tumors (Kuonen et al., 2012a). Furthermore, 
WNT/β-catenin pathway can be aberrantly activated by irradiation exposure, 
resulting in the transcription of β-catenin target genes, including WISP1 (Kim 
et al., 2012). WISP1 is known to be involved in the development of 
radioresistance in esophageal carcinoma cells (Li et al., 2014). To investigate 
whether irradiation of the mammary gland triggers WISP1 expression in mice, 
we analyzed WISP1 mRNA levels in tumors growing either in pre-irradiated 
mammary gland or in untreated tissue. Tumors were initiated by the injection 
of 4T1 mouse mammary tumor cells. WISP1 mRNA levels within the tissue 
homogenates consisting of 4T1 tumors and the tumor stroma were measured. 
As seen in Figure 4, WISP1 mRNA expression in tumors growing in pre-
irradiated mammary glands (IRR_4T1) did not change compared with tumors 
growing in non-irradiated stroma (4T1).  Samples were derived from 8 
different animals per group (pre-irradiated versus non-irradiated). Especially 
for the pre-irradiated group of mice, we observed a high variablility between 
animals resulting in a high standard deviation (Figure 4B).  
 
 
Figure 4: qRT-PCR analysis of WISP1 mRNA expression in tumors growing in pre-irradiated 
stroma versus non-irradiated control stroma. WISP1 expression is normalized to GAPDH in 
tumor tissue homogenates. Primary tumors were initiated by the injection of 4T1 cells into the 
mammary gland of mice. Before injection, the mammary gland was locally irradiated 
(IRR_4T1) or not treated (4T1). A) Each bar represents the mean WISP1 mRNA level ± SD 
from technical replicates within the sample isolated from one animal. There are 8 animals/ 
group. B) Average WISP1 mRNA expression in tumors grown in pre-irradiated stroma versus 
control stroma. Values were normalized towards non-irradiated sample values. Data 
represent means ± SD from 8 samples.    
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2.2.4 WISP1 mRNA expression in pre-irradiated mammary tissue versus 
non-irradiated control tissue 
In many cancers and in WNT1 transgenic mice, WISP1 is localized to the 
tumor stroma surrounding the cancer cells (Gurbuz and Chiquet-Ehrismann, 
2014, submitted). To exclude the possibility that the tumor cells containing low 
levels of WISP1 dominate the stroma and veil the change in WISP1 
expression upon irradiation, we decided to test WISP1 mRNA levels in normal 
mammary gland tissue without the injection of tumor cells. WISP1 mRNA 
levels within the mammary tissue homogenates were measured and 
compared with untreated control tissue. Figure 5 shows a statistically 
significant increase in WISP1 mRNA expression (~1.5 fold) in pre-irradiated 
mammary glands (IRR) compared with non-irradiated tissue (Non_IRR).  
Samples were derived from 8 different animals per group (pre-irradiated 
versus non-irradiated).  
 
 
Figure 5: qRT-PCR analysis of WISP1 mRNA expression in pre-irradiated mammary tissue 
versus non-irradiated control tissue. WISP1 expression is normalized to GAPDH in tissue 
homogenates. The normal mammary gland was locally irradiated (IRR) or not treated 
(Non_IRR). A) Each bar represents the mean WISP1 mRNA level ± SD from technical 
replicates within the sample isolated from one animal. There are 8 animals/ group. B) 
Average WISP1 mRNA expression in tumors grown in pre-irradiated tissue versus control 
tissue. Values were normalized towards non-irradiated sample values. Data represent means 
± SD from 8 samples. t-test revealed a statistically significant difference between the input 
groups (P = 0.042). 
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2.2.5 Generation of cell lines stably overexpressing WISP1 
The positive correlation between the WISP1 mRNA expression and the 
metastatic potential of mouse mammary tumor cells, as well as differential 
WISP1 expression between tumor tissue and normal tissue (Gurbuz and 
Chiquet-Ehrismann, 2014, submitted) prompted us to investigate the 
mechanism of action of WISP1 in a tumor context. We attempted to generate 
mouse mammary epithelial cell lines, HC11 and 4T1 stably overexpressing 
WISP1 to study the effect of increased WISP1 expression on cell behavior in 
vitro and on primary tumor growth and lung metastasis in vivo, respectively. 
By retroviral gene transfer, we introduced a WISP1 gene into the cells. After 
stable selection with relevant antibiotics, we analyzed the protein expression 
by immunofluorescence (IF, Figure 6A) and by immunoblotting (IB, Figure 
6B). In IF staining we could observe a low WISP1 protein expression in the 
majority of stable HC11 cells, while almost no WISP1 expression was 
detected in 4T1 cells. IB confirmed WISP1 expression in HC11 cells, but no 
WISP1 protein was detected in the cell culture media.  
 
 
 
Figure 6: WISP1 protein expression in HC11 and 4T1 cells stably transfected with either 
pQC-Neo (control) or with pQC-WISP1-Neo. A) Immunofluorence staining of intracellular 
WISP1 with anti-myc antibody. B) Immunoblot of intracellular (total cell lysate) and secreted 
(cell culture medium) WISP1 with anti-myc antibody. Samples were run on a 10 % SDS-
PAGE gel. Intracellular WISP1 in COS-7 cells transiently transfected with pCMV6-WISP1 was 
used as positive control. Ponceau S staining of the membrane was used to visualize the BSA 
from the medium as loading control. Molecular weight marker (kDa) is labeled on the left.  
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For the purification of WISP1 protein, we were interested in generating 
mammalian cell lines that express a HIS-tagged variant of WISP1 protein. Our 
aim was to purify the HIS-tagged protein from the cell culture medium of cells 
stably overexpressing WISP1 and to use this recombinant protein either in cell 
functional assays or for antibody production. Published studies suggest that 
WISP1 is involved in both autocrine and paracrine signaling (for review see 
Gurbuz and Chiquet-Ehrismann, 2014, submitted). To test whether these two 
WISP1 signaling mechanisms have different roles in cellular function, we 
decided to compare the effects of endogenous and exogenous proteins. For 
this, in addition to cell lines overexpressing WISP1, we produced recombinant 
WISP1 that could be use as exogenous protein in cell functional assays. It 
was previously shown that overexpression of WISP1 in mammalian cells and 
external addition of the recombinant protein produced in E.coli, had different 
biological effects on cells (Inkson et al., 2008; discussed in Gurbuz and 
Chiquet-Ehrismann, 2014, submitted). Considering the role of post-
translational modifications on protein function we decided to use mammalian 
cells for the expression of the protein.  
 
We attempted to generate EBNA-293 and COS-7 cells stably overexpressing 
WISP1. The human embryonic kidney HEK293-EBNA cells constitutively 
express the Epstein Barr Virus protein EBNA-1, allowing episomal replication 
of the pCEP-Pu vector (Yates et al., 1985; Young et al., 1988). The COS-7 
cell line was derived from CV-1 kidney cells of the African Green Monkey, 
Cercopithecus aethiops through transformation with the Simian Vacuolating 
Virus 40 (Gluzman 1981). We introduced the HIS-tagged WISP1 gene into the 
two cell lines. After stable selection with relevant antibiotics, we analyzed the 
protein expression by IF (Figure 7A) and by IB (Figure 7B). IF staining 
showed that a high percentage of both EBNA-293 and COS-7 cells were 
expressing WISP1 protein. IB of WISP1 in lysates of EBNA-293 and COS-7 
cells confirmed the protein expression. The cell culture medium of COS-7 
cells was positive for WISP1 protein expression, and the size of the secreted 
protein was larger than the intracellular form (discussed in chapter 2.2.6).  
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No secreted protein was detected in the cell culture medium of EBNA-293 
cells. To test whether EBNA-293 cells were not able to secrete WISP1 or the 
secreted protein was below the detection limit by IB, we precipicated the 
proteins in the EBNA-293 cell culture medium with TCA (Figure 7B). Upon 
TCA precipitation, we were able to detect secreted WISP1 in EBNA-293 cells. 
Since WISP1 protein concentration in the cell culture medium of EBNA-293 
cells was low, we decided to use COS-7 cells for recombinant protein 
expression and subsequent protein purification.  
 
 
 
 
Figure 7: WISP1 protein expression in EBNA-293 and COS-7 cells stably transfected with 
pCEP-Pu-WISP1-HIS. A) Immunofluorence staining of intracellular WISP1 with anti-myc 
antibody. B) Immunoblot of intracellular (total cell lysate) and secreted (cell culture medium) 
WISP1 with anti-myc antibody. Samples were run on a 10 % SDS-PAGE gel. To analyze the 
presence of secreted WISP1 in EBNA-293-WISP1 cell culture, proteins were precipicated 
with TCA. For total cell lysates vinculin (116 kDa), for cell culture media BSA (70 kDa) stained 
with Ponceau S serves as loading controls. Molecular weight marker (kDa) is labeled on the 
left.  
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2.2.6 WISP1 is a glycosylated protein 
IB of intracellular and secreted WISP1 showed that the secreted form of the 
protein has a higher molecular weight (~65 kDa) compared to the intracellular 
form (~52 kDa), and that the observed molecular weights are different than 
the predicted molecular weights (predicted molecular weight of intracellular 
WISP1: 40 kDa, predicted molecular weight of secreted WISP1: 38 kDa) 
(Figure 8A). This observation prompted us to analyze the post-translational 
modification status of WISP1.  
 
In 1998 Pennica et al., reported for the first time that WISP1 has four potential 
N-linked glycosylation sites. Later on, different studies showed that WISP1 is 
post-translationally modified and that these modifications affect its biological 
function (Gurbuz and Chiquet-Ehrismann, 2014, submitted). Furthermore, 
experimentally it was proven that other CCN proteins, CCN2/CTGF and 
CCN3/NOV, are N-glycosylated (Bohr et al., 2010). Inkson et al. (2008) 
observed that total cell lysates from hBMSC reveal expression of a WISP1 
protein with a larger molecular weight than predicted, and larger than that of 
the recombinant WISP1 (human, prepared in E.coli). 
 
The in silico prediction of potential N-Glycosylation sites on the WISP1 protein 
sequence is shown in figure 8B. In order to confirm the prediction, we N-
deglycosylated the protein by using PNGase F (Figure 8C). PNGase F is an 
amidase that cleaves between the innermost GlcNAc and asparagine 
residues and removes high mannose, hybrid and complex oligosaccharides 
from N-linked glycoproteins (Maley et al., 1989). PNGase F treatment resulted 
in a shift of the protein band of both intracellular and secreted WISP1. This 
result shows that both forms of WISP1 are N-glycosylated. However the 
secreted WISP1 must undergo additional post-translational modifications, 
possibly other types of complex glycosylations, which cannot be removed by 
PNGase F treatment.  
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Figure 8: WISP1 is a N-glycosylated protein. A) Immunoblot with anti-myc antibody of 
intracellular (total cell lysate) and secreted (cell culture media) WISP1 in COS-7 cells 
transiently transfected  with pCMV6-WISP1. Samples were run on a 10 % SDS-PAGE gel. 
Ponceau S staining of the membrane was used to visualize the BSA from the medium as 
loading control. Molecular weight marker (kDa) is labeled on the left. Secreted WISP1 has a 
higher molecular weight than the intracellular WISP1. B) N-glycosylation sites within WISP1 
protein sequence were predicted using NetNGlyc 1.0 server. Xaa-Ser/Thr sequons are 
highlighted in blue. Asparagines predicted to be N-glycosylated are highlighted in red. Below, 
N-glycosylation site prediction is represented by a graph. C) Immunoblot as explained in A. 
For deglycosylation, protein samples (total cell lysate and cell culture medium) were treated 
with PNGase F. RNase B, positive deglycosylation control, was stained with Coomassie Blue 
dye. All samples were run on a 12.5 % SDS-PAGE gel. Both intracellular and secreted WISP1 
are N-glycosylated.  
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2.2.7 HC11 cells stably overexpressing WISP1 show distinct proliferation 
rates and migration behaviors  
To analyze the effect of WISP1 on cell behavior, we used HC11 cells stably 
overexpressing WISP1. Since WISP1 is known to have a function in cancer 
(Gurbuz and Chiquet-Ehrismann, 2014, submitted), we decided to analyze 
two main cell functions important for cancer progression: proliferation and cell 
migration. An HC11 cell strain stably transfected with an empty vector 
expressing only endogenous WISP1 served as a negative control in these 
studies. The proliferation rates of HC11 cells were analyzed using a 5-bromo-
2′-deoxyuridine (BrdU) incorporation assay. The incorporated BrdU was 
measured at 24, 48 and 72 hours after plating. Compared with empty vector-
transfected control HC11 cells, there was an increase in BrdU incorporation in 
HC11-WISP1 cells over the entire time period tested (Figure 9A). The 
difference in cell growth was not due to decreased cell death rate in HC11-
WISP1 cells, as we have not observed any changes in cell viability (Figure 
9B). To investigate cell migration, we used wound healing scratch assays. 
After 12 hours, we did not observe any major difference in wound closure rate 
(Figure 9C). However, to close the gap, HC11-WISP1 cells seemed to exhibit 
a different cell locomotion mechanism compared with the control cell line. 
Whereas HC11-WISP1 cells migrated collectively as continuous sheets in a 
sliding fashion, HC11-empty cells near the wound margin crawled as 
individual cells. In conclusion, overexpression of WISP1 protein in HC11 cells 
led to an increase in cell proliferation and changed the mechanism of cell 
motility without affecting cell viability.  
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Figure 9: HC11 cells stably overexpressing WISP1 show distinct proliferation rates and 
migration behaviors. WISP1 does not affect HC11 cell viability. A) Proliferation rates of HC11 
cells were assessed by BrdU incorporation into newly synthesized DNA at 24, 48 and 72 
hours. Each line represents the mean BrdU incorporation ± SD from technical replicates. B) 
The viability of HC11 cells was analyzed by CellTiter-Blue® assay. The fluorescent signal is 
proportional to the number of viable cells. No change in cell viability was observed upon 
WISP1 overexpression. Each line represents the mean fluorescence value ± SD from 
technical replicates. C) HC11 cell migration was evaluated by wound healing scratch assay. 
After 12 hours of incubation, the images of cells infiltrating the scratch were recorded.   
 
 
 
 
 
 
 
 
	
   69	
  
2.2.8 COS-7 cells stably overexpressing WISP1 show distinct 
proliferation rates and migration behaviors 
To analyze the role of WISP1 in cell proliferation and migration, in addition to 
mouse mammary epithelial HC11 cells, we used COS-7 cells stably 
overexpressing the HIS-tagged variant of WISP1. Although COS-7 cells are 
not frequently used in cell behavior assays, we decided to use our COS-7-
WISP1 cell line, because these cells had a high intracellular WISP1 protein 
expression level and were able to secrete a reasonable amount of protein in 
the cell culture medium (Figure 7B). Parental COS-7 cells served as negative 
controls in these studies. As for HC11 cells, the proliferation rates of COS-7 
cells were analyzed using BrdU incorporation assay. The incorporated BrdU 
was measured at 24, 48 and 72 hours. Compared with parental control COS-7 
cells, there was a decrease in BrdU incorporation in COS-7-WISP1 cells over 
the entire time period tested (Figure 10A). The difference in cell growth was 
not due to increased cell death rate in COS-7-WISP1 cells, as we have not 
observed any changes in cell viability (Figure 10B). To analyze cell motility, 
we used wound healing scratch assay as well as Boyden Chamber Migration 
assay. Wound healing assay showed that COS-7 cells stably overexpressing 
WISP1 were faster in closing the gap compared with the wild-type controls 
(Figure 10C). On the other hand, in Boyden Chamber Migration assay we 
observed that the overexpression of WISP1 downregulated COS-7 cell 
migration by ~1.4 fold compared with endogenous WISP1 expression in 
parental COS-7 cells (Figure 10D). In summary, the effect of WISP1 on cell 
proliferation seems to be cell type dependent as opposite effects were 
observed in HC11 and COS-7 cells. Moreover, the role of WISP1 in cell 
motility varies depending on the assay used. WISP1 overexpression does not 
have an impact on HC11 or COS-7 cell viability. 
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Figure 10: COS-7 cells stably overexpressing WISP1 show distinct proliferation rates and 
migration behaviors. WISP1 does not affect COS-7 cell viability. A) Proliferation rates of COS-
7 cells were assessed by BrdU incorporation into newly synthesized DNA at 24, 48 and 72 
hours. Each line represents the mean BrdU incorporation ± SD from technical replicates. B) 
The viability of COS-7 cells was analyzed by CellTiter-Blue® assay. The fluorescent signal is 
proportional to the number of viable cells. No change in cell viabiliy was observed upon 
WISP1 overexpression. Each line represents the mean fluorescence value ± SD from 
technical replicates. C) COS-7 cell migration was evaluated by wound healing scratch assay 
(C) and Boyden Chamber migration assay using filters with 8 µm pore size (D). C) After 12 
hours of incubation, the images of cells infiltrating the scratch were recorded. D) 
Quantification of COS-7 cell migration towards 10% FCS was measured by the area on the 
lower side of the filter covered with cells. Values were normalized towards the total area 
covered by migrated COS-7-WT cells. Each bar represents the mean area ± SD from 
technical replicates. Representative photos of fixed and stained cells that have migrated to 
the lower side of the filter are shown above the bar graph.  
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2.2.9 Purification of WISP1 protein and polyclonal anti-WISP1 antiserum 
production 
So far, in our experiments we used commercially available WISP1 antibodies 
that were generated against a peptide sequence of WISP1 (Gurbuz et al., 
2014). However in immunoblotting, we observed non-specific binding of the 
commercial antibodies. For immunostaining a specific antibody without cross-
reactivity with other proteins is needed. Thus, we decided to produce antisera 
against the entire protein.  
 
Recombinant WISP1 was purified from the cell culture medium of COS-7 cells 
stably overexpressing the HIS-tagged variant of WISP1 (Figure 11). 2 rabbits, 
SY6205 and SY6206, were immunized with the soluble recombinant WISP1 
protein and sera from the animals containing the polyclonal anti-WISP1 
antibodies, SAB-SY6205 and SAB-SY6206, were obtained. The quality of the 
anti-WISP1 antibodies in the rabbit sera were tested by IF and IB (Figure 12). 
Large bleed samples of the anti-WISP1 antibodies were compared with the 
anti-myc antibody, as well as with the pre-immune sera (Figures 12A and 
12C). To find the optimal antibody concentration, different dilutions were 
tested. Pre-immune test bleed served as a negative control since it was 
collected from the same animal that was used to generate the antibody before 
immunization. The large test bleed was used to monitor the antibody titer. The 
IB showed that both antibodies were able to recognize the intracellular WISP1 
at ~52 kDa in cell lysates of WISP1-transfected cells. The pre-immune sera 
PPI-SY6205 and PPI-SY6206 did not bind to WISP1, which proves the 
specificity of the antibodies. SAB-SY6206 showed a higher affinity towards 
WISP1 than SAB-SY6205; even 1:2000 dilution of the antibody was able to 
detect the protein. For both antibodies 1:1000 seemed to be the optimum 
concentration. Although both antibodies recognized WISP1, they also showed 
cross-reactivity towards an unspecific protein at ~45 kDa. To test whether the 
antibodies recognize secreted WISP1 in the cell culture medium we 
performed another IB. This time, we incubated the entire membrane with anti-
WISP1 antibodies diluted 1:1000 to test whether they bind to additional 
unspecific proteins (Figures 12B and 12D). Both SAB-SY6205 and SAB-
SY6206 were able to recognize the secreted WISP1 at ~65 kDa in cell culture 
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media of WISP1-transfected cells. In addition to the unspecific protein 
detected at ~45 kDa, another cross-reactivity was observed at ~250 kDa. The 
unspecific binding at ~250 kDa was weaker for SAB-SY6205 than for SAB-
SY6206. Mass Spectrometry Analysis showed that the non-specific proteins 
recognized by the anti-WISP1 antibodies at ~45 kDa and ~250 kDa were 
plasminogen activator inhibitor type 1 (PAI1) and fibronectin (FN), 
respectively. Last but not least, SAB-SY6206 anti-WISP1 antibody was tested 
in immunofluorescence staining and compared with anti-myc antibody (Figure 
12E). SAB-SY6206 was able to detect intracellular WISP1 in 67NR cells 
transiently transfected with WISP1.  
 
 
 
Figure 11: Coomassie-stained gel of protein purification steps. HIS-tagged, secreted WISP1 
is purified from the serum free cell culture medium of COS-7 cells stably transfected with 
pCEP-Pu-WISP1-HIS. Soluble proteins were precipitated with ammonium sulfate, dialyzed 
against PBS and affinity purified on Ni-NTA resin. WISP1 was eluted with imidazole. Eluted 
proteins (24 µl/ well) were run on a 10 % SDS-PAGE gel and stained with Coomassie Blue 
dye. WISP1 is indicated by arrowhead. Molecular weight marker (kDa) is labeled on the left. 
The eluates marked with the red rectangle were used as the antigens for the polyclonal 
antibody production.  
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Figure 12: Characterization of anti-WISP1 rabbit polyclonal antibodies. 2 Rabbits (SY6205 
and SY6206) were immunized with the recombinant WISP1 produced in COS-7 cells. Pre-
immune serum (PPI, Day: 0), large bleed (GP, Day: 21) and final bleed (SAB, Day: 28) were 
tested. Immunoblot of intracellular (total cell lysate) WISP1 with anti-myc antibody (1:100), 
PPI-SY6205 (1:100), GP-SY6205 (1:100), SAB-SY6205 (1:100-1:2000) (A) and with anti-myc 
antibody (1:100), PPI-SY6206 (1:100), GP-SY6206 (1:100), SAB-SY6206 (1:100-1:2000) (C). 
Total cell lysates isolated from parental COS-7 cells or from COS-7 cells transiently 
transfected with pCMV6-WISP1 were run on a 10 % SDS-PAGE gel. Vinculin (116 kDa) 
served as loading control. Immunoblot of intracellular (total cell lysate) and secreted (cell 
culture medium) WISP1 with SAB-SY6205 (B) and SAB-SY6206 (D) antibodies. Samples 
were run on a 7.5 % SDS-PAGE gel. The locations of FN (fibronectin, 263 kDa, human), 
WISP1 (secreted and intracellular, mouse) PAI1 (plasminogen activator inhibitor type 1, 45 
kDa, human) are indicated. Molecular weight marker (kDa) is labeled on the left side of the 
blots. E) Immunofluorescence staining of intracellular WISP1 in 67NR cells transiently 
transfected with with pCMV6-WISP1. 67NR cells were stained with anti-myc primary antibody 
(1:20) and Alexa488-labeled secondary antibody (1:1000) or with SAB-SY6206 primary 
antibody (1:1000) and Alexa568-labeled secondary antibody (1:1000).  
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CHAPTER 3: DISCUSSION AND FUTURE DIRECTIONS 
 
Previous work from our group revealed that Megakaryoblastic leukemia 1 
(MKL1) acts as a bona fide transcription factor in mechanotransduction and 
mediates serum response factor (SRF)-independent, SAP-domain dependent 
transcription of cyclic stretch-induced tenascin-C (TNC) expression 
(Asparuhova et al., 2011). We were interested in identifying additional MKL1 
target genes co-regulated with TNC and to analyze whether such genes could 
be implicated in cancer progression.  
 
In the present work we discovered SRF-independent, SAP domain-dependent 
MKL1 target genes that are implicated in cell proliferation and motility, and 
found that these genes are elevated in breast cancer patients with poor 
survival (Discussed in detail in Gurbuz et al. 2014). From this group of genes 
WNT1 inducible signaling pathway protein 1 (WISP1) caught our interest. Xu 
et al. (2000) reported that WISP1 is a β-catenin responsive oncogene. Like 
TNC, WISP1 is transiently expressed during embryonic development, wound 
healing and tissue remodeling, and its aberrant expression is associated with 
various pathologies including cancer (Chiquet-Ehrismann and Chiquet, 2003; 
Gurbuz and Chiquet-Ehrismann, 2014, submitted). Transcript profiling studies 
available from the Oncomine database revealed increased WISP1 expression 
in many human cancers (Gurbuz and Chiquet-Ehrismann, 2014, submitted). 
Despite of a considerable number of data showing increased WISP1 
expression in cancer, relatively little is known about the mechanistic details of 
its function. Therefore, we focused on the biochemical and cell biological 
characterization of the WISP1 protein, as well as its role in cancer 
progression. 
 
3.1 Cell biological characterization of WISP1 
Yang et al. (2004) hypothesized that the altered expression of a specific group 
of genes causes the metastatic properties of the four isogenic mouse 
mammary tumor cells lines, 67NR, 168FARN, 4T07 and 4T1. They compared 
the transcription profiles of the four tumor cell lines and identified several 
differentially expressed genes. Among these genes, they focused on the 
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transcription factor Twist that was strongly upregulated in 168FARN, 4TO7, 
and 4T1 tumor cells compared to 67NR cells, and investigated its mechanistic 
role in promoting metastasis. When we tested the mRNA levels of WISP1 in 
these four cell lines, we observed the same tendency. Endogenous WISP1 
expression positively correlated with the metastatic potential of the cells. 
Since WISP1 expression increases during cellular processes that require cell 
migration and ECM remodeling (Berschneider and Konigshoff, 2011), we think 
that increased WISP1 levels might play a stimulatory role in tumor invasion 
and metastasis.  
 
As summarized before (chapter 1.1.5), ionizing radiation alters the tissue 
microenvironment and may contribute to tumor progression. Experimental 
tumors growing in pre-irradiated mammary tissue were more metastatic 
compared to tumors growing in normal stroma (Milas et al., 1988; Kuonen et 
al., 2012a). Furthermore, tumor cells isolated from glioblastoma xenografts 
after in vivo ionizing radiation had an activated WNT/β-catenin signaling 
pathway and increased transcription of β-catenin target genes, including 
WISP1 (Kim et al., 2012). WISP1 expression has been associated with tumor 
progression and poor prognosis in patients with many different types of solid 
tumors (Gurbuz and Chiquet-Ehrismann, 2014, submitted). Furthermore, as 
mentioned in the previous paragraph, we observed a positive correlation 
between the metastatic potential of mouse mammary tumor cell lines and 
WISP1 expression. Considering the contribution of irradiation to metastasis, 
we hypothesized that WISP1 might be one of the players mediating this effect. 
To investigate whether irradiation triggers WISP1 expression in an orthotopic 
breast cancer model, we analyzed WISP1 mRNA levels in 4T1 tumors 
growing either in pre-irradiated mammary gland or in untreated tissue. When 
we analyzed tumor tissue homogenates, we could not detect any significant 
changes in WISP1 expression upon irradiation. However, since WISP1 is 
predominantly expressed within the stroma rather than the epithelial tumor 
cells (Gurbuz and Chiquet-Ehrismann, 2014, submitted), we were interested 
in seeing the radiation-induced response of the normal mammary gland 
without injection of tumor cells. For this, we tested the WISP1 expression in 
normal mammary gland tissue without tumors and observed a significant 
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increase in WISP1 expression upon irradiation. Future studies that uncover 
the mechanism of how radiation activates WISP1 expression and how this 
activation contributes to tumor metastasis are warranted.  
 
To study the cell biological function of WISP1 in cell proliferation and 
migration in vitro and in primary tumor growth and lung metastasis in vivo, we 
decided to generate cell lines stably overexpressing WISP1. We introduced 
the WISP1 gene into normal HC11 and transformed 4T1 mouse mammary 
epithelial cells and selected for cells that have stably incorporated the plasmid 
into their genomic DNA. Most of the antibiotic-resistant HC11 cells were also 
positive for WISP1 expression, although the level of expression was low. On 
the other hand, almost no WISP1 expression was detected in 4T1 cells. Either 
in the long term 4T1 cells cannot tolerate WISP1 expression and as result 
cells with the resistance gene only but without WISP1 are taking over or in our 
experiments the selective pressure was not strong enough.  
 
The other cell lines generated were EBNA-293 and COS-7 cells stably 
overexpressing WISP1. After selection with antibiotics both cell lines were 
positive for WISP1 expression. However secreted WISP1 was detected in the 
cell culture medium of EBNA-293 cells only after TCA precipitation showing 
that in EBNA-293 cells, the concentration of secreted WISP1 was low. Either 
the cells produced not enough protein, or they were not able to secrete the 
protein efficiently. It is possible that EBNA-293 could only tolerate 
intermediate levels of WISP1. On the other hand, COS-7 cells expressed and 
secreted easily detectable amounts of WISP1 protein. Among all four stable 
cell lines (HC11, 4T1, EBNA-293, COS-7), COS-7 cells exhibited the highest 
amount of intracellular and secreted WISP1 protein within the total cell lysates 
and cell culture medium, respectively. Although, normally the EBNA-293 cell 
line is the most suitable model for recombinant protein expression and 
subsequent protein purification, due to low endogenous secreted proteins 
within the cell culture medium, we could not use this cell line. Hence, for 
protein purification we expanded COS-7 cells that stably overexpress WISP1. 
Nevertheless, the concentration of the recombinant WISP1 was low. This may 
be due to the fact that even COS-7 cell do not produce that large amounts of 
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WISP1 protein. Another possibility is that we lost some protein during the 
purification process. According to the literature, biologically active CCN 
proteins are difficult to purify, presumably because of the high number of 
cysteine residues (Leask and Abraham, 2006; Inkson et al., 2008; Chen and 
Lau, 2009). Using the small amount of protein we had, we performed cell 
migration assays by either direct addition of the recombinant protein to the cell 
culture media or by coating the transwell inserts with the recombinant protein. 
However, we were not able to see any significant difference in cell migration 
compared with the controls (data not shown).  
 
Most of the purified WISP1 was used to immunize two rabbits. We could 
obtain 2 different polyclonal anti-WISP1 antibodies, SAB-SY6205 and SAB-
SY6206. Both SAB-SY6205 and SAB-SY6206 could specifically recognize the 
intracellular and the secreted forms of WISP1 at the expected sizes (~52 kDa 
and ~65 kDa, respectively). However, both antibodies showed cross-reactivity 
with two other proteins, plasminogen activator inhibitor type 1 (PAI1) and 
fibronectin (FN). According to the Mass Spectrometry Analysis, the 
contaminants FN and PAI1 were human proteins. Since human and monkey 
proteins have a high sequence similarity we assume that these proteins 
originate from the COS-7 monkey cells. Nevertheless, since the polyclonal 
WISP1 antibodies recognize one specific band at the right size, only in 
transfected cells, they can be used for immunoblotting. However, due to the 
cross-reactivity with FN and PAI1, they cannot be used in immunostaining as 
is. In the future, we are planning to use the antibodies to analyze WISP1 
protein expression in cancer tissue microarrays. For this, we have to remove 
the cross-reactivity of the antibodies by absorption to FN and PAI1.  
 
Since we could not generate 4T1 cell lines that stably overexpress WISP1, we 
were not able to continue our planned in vivo experiments. Nevertheless, by 
using stable HC11 and COS-7 cell lines we performed cell biological assays. 
We analyzed cell proliferation, migration, and survival, three main cellular 
functions that are frequently deregulated in cancer. First of all, WISP1 had no 
effect on cell survival in both cell lines tested, as we have not observed any 
changes in cell viability upon WISP1 overexpression. Compared with empty 
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vector-transfected control cells, HC11-WISP1 cells showed increased 
proliferation suggesting that endogenous WISP1 expression positively affects 
cell proliferation in HC11 mammary epithelial cells. In support of that, it has 
previously been shown that overexpression of WISP1 induces proliferation of 
human bone marrow stroma cells (Inkson et al., 2008). In contrast to these 
observations, endogenous WISP1 had a negative effect on COS-7 cell 
proliferation as we have observed a decrease in BrdU incorporation in COS-7-
WISP1 cells compared with their parental controls. It is possible that the role 
of WISP1 in cell proliferation depends on the cellular system used. In addition, 
we have to keep in mind that parental COS-7 cells do not serve as the proper 
controls, since they have not been transfected and they have not been treated 
with antibiotics. In the future, we are planning to repeat this proliferation assay 
by using empty vector-transfected control cells.  
 
To test the effect of WISP1 on cell migration, first we performed wound 
healing scratch assays. Although we didn’t observe any major difference in 
the wound closure rate of HC11-WISP1 cells compared to the controls, the 
mode of cell migration seemed different. HC11-WISP1 cells exhibited 
collective, gliding-type migration while HC11-empty cells at the wound edge 
migrated as single units. Cells move either individually or collectively 
depending on the absence or presence of cell-cell junctions (Friedl and Wolf, 
2009). Collective cell migration is involved in tissue regeneration and can 
contribute to metastasis by local invasion (Friedl and Wolf, 2009). Considering 
the role of WISP1 in wound healing, tissue remodeling and tumor progression, 
we can speculate that endogenous WISP1 expression induces single-cell-to-
collective transition and results in a change in the mode of migration by 
enhancing cell-cell adhesions. This needs to be addressed and verified in 
detail in further experiments. In addition it would be interesting to test the 
effect of endogenous WISP1 on cell adhesion.  
 
Unlike HC11 cells, COS-7 cells exhibited a clear difference in wound closure 
rate. COS-7 cells that stably overexpress WISP1 were faster in closing the 
gap compared with the wild-type controls. Intuitively, one would expect that 
the untreated parental cells are more “fit” and move faster compared to the 
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cells that went through transfection and an antibiotic selection process. With 
this in mind we conclude that forced WISP1 expression may indeed contribute 
to undirected cell migration in COS-7 cells. In contrast, in Boyden Chamber 
Migration assay we observed that the overexpression of WISP1 
downregulated COS-7 cell migration compared with parental controls. In line 
with our observation, in a previous study it has been reported that 
overexpression of WISP1 downregulates the motility of H460 and H1299 lung 
cancer cells that were plated in Boyden chambers and induced to migrate 
towards a serum gradient (1.5% FBS) (Soon et al., 2003). There may be 
different reasons for the apparent contradictory results obtained in two cell 
motility assays. First, wound healing scratch assays and Boyden Chamber 
migration assays are two different experimental systems. In the wound 
healing assay random cell motility is analyzed, whereas Boyden Chamber 
migration assay is used to test directed cell motility towards a soluble 
chemoattractant (i.e. serum). Second, COS-7 cells might have different 
modes of migration. If we assume that COS-7-WISP1 cells migrate 
collectively as cohesive multicellular units, we can speculate that the cellular 
aggregates formed cannot get through the pores of the transwell inserts. On 
the other hand, COS-WT cells that migrate individually can easily go through 
the pores. The difference between the migration patterns of COS-7 cells might 
give us a wrong impression about their migration speeds. An additional cell 
motility assay, such as time-lapse microscopy of live cell migration might be 
useful to clarify the role of endogenous WISP1 in HC11 and COS-7 cell 
migration.  
 
In a range of tumors, WISP1 expression is localized to the tumor stroma 
surrounding the epithelial cancer cells (Gurbuz and Chiquet-Ehrismann, 2014, 
submitted). This suggests that WISP1 might be an oncogenic factor that is 
secreted by stromal fibroblasts to stimulate epithelial tumor progression in a 
paracrine manner. It would be interesting to study the effect of paracrine 
WISP1 signaling on cell proliferation and migration in vitro and on primary 
tumor growth and lung metastasis in vivo. For this purpose we are planning to 
generate BalbC-3T3 fibroblasts that stably overexpress WISP1 and to use 
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these stromal cells together with the isogenic mouse mammary tumor cells 
lines, 67NR, 168FARN, 4T07 and 4T1 in in vivo studies.  
 
3.2 Biochemical characterization of WISP1: Post-translational 
modifications  
 
Immunoblots of intracellular and secreted WISP1 showed that the secreted 
form of the protein has a higher molecular weight compared to the intracellular 
form, and that the observed molecular weights are different than the predicted 
molecular weights. The covalent attachment of carbohydrates, glycosylation is 
the most common post-translational protein modification that is conserved 
from bacteria to eukaryotes (Spiro, 2002; Hess et al., 2008; Lommel and 
Strahl, 2009). Various carbohydrate-peptide linkages have been reported that 
increase the functional diversity of the protein (Spiro, 2002). Attached 
carbohydrates can interfere with the cellular localization, turnover and ligand 
interaction capacity of a protein (Lommel and Strahl, 2009). The glycopeptide 
bonds are distributed into five main groups: N-glycosidic bonds, O-glycosidic 
bonds, C-mannosyl bonds, phosphoglycosyl bonds and glypiated bonds 
(Spiro, 2002). Attachment of GlcNAc to asparagine is the most common 
carbohydrate-peptide bond (Spiro, 2002). Studies showed that the 
recombinant CCN2/CTGF and CCN3/NOV are N-glycosylated (Bohr et al., 
2010). Moreover, according to in silico prediction data, WISP1 protein 
sequence possesses 4 potential N-glycosylation sites. By PNGase F 
treatment we could confirm that both the intracellular and secreted WISP1 
proteins are N-glycosylated. However, after N-deglycosylation, the two 
proteins were still different in size. This observation suggests that the 
secreted WISP1 undergoes additional post-translational modifications, which 
cannot be removed by PGNase F treatment. 
 
Hofsteenge et al. showed that thrombospondin type 1 (TSP1) repeats are 
subject to two types of glycosylations: C-mannosylation and O-fucosylation 
(Hofsteenge et al., 2001). TSP1 repeats are found in several secreted or cell-
surface proteins, such as thrombospondins and CCN family members, 
including WISP1 (Hofsteenge et al., 2001; Leonhard-Melief and Haltiwanger, 
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2010; Jun and Lau, 2011). TSP1 repeats contain conserved tryptophan 
residues in a “WXXW” pattern, the recognition motifs for protein C-
mannosylation (Hofsteenge et al., 2001). Analysis of human and mouse 
WISP1 revealed that this recognition motif does not exist in the WISP1 protein 
sequence. In O-glycosylation, sugar residues get attached to an amino acid 
containing a hydroxyl group (e.g. serine, threonine, tyrosine, hydroxyproline, 
and hydroxylysine) (Spiro, 2002; Lommel and Strahl, 2009). TSP1 repeats are 
found to contain an O-linked disaccharide “Glc-Fuc-O” on the threonine or 
serine residues in the sequence “CXX(S/T)CG” (Hofsteenge et al., 2001). We 
could indeed detect this O-fucosylation motif on the mouse (CSX(T)CG) and 
human (CSX(S)CG) WISP1 protein sequence within the TSP1 domain. 
Several other matricellular proteins, including thrombospondins, ADAMTS (A 
Distintegrin And Metalloprotease with Thrombospondin type 1 repeats), and 
CCNs (CCN1/CYR61, CCN2/CTGF, CCN3/NOV, CCN6/WISP3) are reported 
to contain O-fucosylation motifs (Leonhard-Melief and Haltiwanger, 2010). 
Protein fucosylation has been implicated in pathological conditions, such as 
inflammation and cancer, and certain types of fucosylated glycoproteins have 
been used as tumor markers (Miyoshi et al., 2008). Taken together, it would 
be interesting to confirm the O-fucosylation of WISP1 and to investigate the 
role of this particular post-translational modification in a tumor context.  
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CHAPTER 4: APPENDIX  
 
4.1 Experimental Procedures (Unpublished Results) 
 
Cell culture and gene transfers 
Mouse mammary epithelial HC11 cells were grown in RPMI-1640 medium 
supplemented with 10% FCS, 5 µg/ml insulin (Sigma, Buchs, Switzerland) 
and 10 ng/ml epidermal growth factor (EGF; Invitrogen, Zug, Switzerland). 
Isogenic mouse breast cancer cells, 67NR, 168FARN, 4T07 and 4T1, as well 
as human embryonic kidney HEK293-EBNA cells and African Green Monkey 
kidney cells COS-7 were grown in DMEM medium supplemented with 10% 
FCS.  
 
The mammalian expression vector pCMV6-WISP1 (C-terminal Myc and DDK 
Tagged) was purchased from Origene (MR205645, Wisp1 (NM_018865) 
Mouse cDNA ORF Clone, OriGene, Rockville, MD, USA). COS-7 and 67NR 
cells were transfected using FuGENE® 6 (Roche, Basel, Switzerland) and 
jetPEI® DNA transfection reagent (Polyplus), respectively according to the 
manufacturers’ instructions.  
 
To obtain cells stably expressing WISP1, retroviral gene transfer and 
subsequent selection were performed. First, full-length WISP1 cDNA  
(MR205645, OriGene, Rockville, MD, USA) was amplified by PCR adding 
AgeI and PacI restriction sites at the 5’ and 3’ ends, respectively, followed by 
a stop codon at the C-terminus using the following primers: 5′-
ATACCGGTATGAGGTGGCTCCTGCCCTG-3’ (forward primer) and 5’-
ATTTAATTAATTACAGATCCTCTTCTGAGATGAG-3’ (reverse primer). 
During the cDNA amplification the DKK-tag was removed whereas the myc-
tag was conserved. The amplified fragments were subsequently cloned in the 
multiple cloning site II of the bicistronic pQCXIX Retroviral Vector (Clontech 
Laboratories, Mountain View, CA USA) plasmid. The selection marker 
neomycin (Neo) has been previously cloned in the multiple cloning site II of 
pQCXIX vector as described (Asparuhova et al., 2011) resulting in pQCX-
Neo. The packaging cells EcoPack2TM-293 (Cat.No: 631507, Clontech 
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Laboratories, Mountain View, CA USA) were transfected using TransIT®-293 
Transfection Reagent (Mirus Bio LLC., WI,  USA) according to the 
manufacturer’s protocol. The supernatant of EcoPack2TM-293 cells containing 
the virus was collected and used to infect the target 4T1 and HC11 cells. The 
infection was performed as described in the manufacturer’s manual. To obtain 
4T1 and HC11 cells stably expressing WISP1, cells were selected with 
Geneticin (1 mg/ml; Roche). To generate control cell lines, cells were 
transfected with pQCX-Neo vectors that lack the WISP1 gene and were 
selected with Geneticin (1 mg/ml; Roche). 
 
For recombinant protein affinity purification, a polyhistidine-tag was added at 
the C-terminus of the coding sequence of WISP1.  For this, full-length WISP1 
cDNA was amplified by PCR from the mouse WISP1 clone (MR205645, 
OriGene, Rockville, MD, USA) using the following primers: 5′-
TCAGAATTTTGTAATACGACTC-3′  (forward primer) and 5′-
ATGCTAGCTCAGTGATGGTGATGGTGATGCAGATCCTCTTCTGAGATGA
G-3′ (reverse primer). WISP1 was amplified adding NheI restriction site at the 
3’ end, as well as a sequence encoding 6 histidines (CAT-CAC-CAT-CAC-
CAT-CAC) followed by a stop codon at the C-terminus. During the cDNA 
amplification the DKK-tag was removed whereas the myc-tag was conserved. 
The amplified fragments were subsequently cloned into the expression vector 
pCEP-Pu (provided by J. Engel, Biozentrum, Basel, Switzerland). To generate 
cell lines stably overexpressing the HIS-tagged variant of WISP1, HEK293-
EBNA and COS-7 cells were transfected with 3 µg of the expression plasmid 
using jetPEI® DNA transfection reagent (Polyplus). After 24 hours of culture, 
transfected HEK293-EBNA and COS-7 cells were selected with 1 µg/ml 
puromycin and with 4.5 µg/ml puromycin, respectively.   
 
All clones were verified by DNA sequencing. (For vector information, see 
Chapter 4.2, Supplementary Figure 2) 
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Protein purification from mammalian cells and subsequent polyclonal 
antibody production 
COS-7 cells stably overexpressing the HIS-tagged variant of WISP1 were 
expanded in 3-layer flasks. After they reached confluency, cells were washed 
3 times with serum-free DMEM media and new serum-free culture media 
were added to the cells. After 48 hours of incubation, serum free media 
containing recombinant soluble protein were collected and stored at -80°C. 
This media collection procedure was repeated 6 times. Collected media were 
pooled and proteins present in these conditioned media were precipitated with 
ammonium sulfate (440 g/ 1 l medium) and dialyzed against PBS using 12-14 
kDa cut-off dialysis bags (Regenerated cellulose tubular membrane, 
Cellu.Sep®, Uptima). This was followed by affinity purification on Ni-NTA resin 
(Invitrogen). After washing of the column with 20 mM, 50 mM, 100 mM and 
200 mM imidazole, the protein was eluted with 300 mM imidazole. To 
visualize the presence of purified WISP1, protein samples (24 µl/ well) were 
loaded and run on 10% SDS gels. Gels were stained with InstantBlueTM 
(Coomassie Blue® based stain, Expedeon). 
 
Fractions in elution buffer (300 mM Imidazole, 0.9 M NaCl, physiological 
buffer) contained approximately 225 µg of purified WISP1 protein distributed 
among 8 aliquots. These samples were sent to the custom antibody 
production company (Eurogentec SA, Seraing, Belgium). Two rabbits (Animal 
1: SY6205, Animal 2: SY6206) were immunized according to the speedy 28-
day protocol (4 injections, 3 bleeds). Pre-immune serum (PPI, Day: 0), large 
bleed (GP, Day: 21) and final bleed (SAB, Day: 28) were received and used in 
immunoblotting and immunofluorescence assays as described.  
 
Cell Viability Assay  
Different numbers of COS-7 and HC11 cells (between 9×104 and ~3×102) 
were plated in triplicates on 96-well plates in serum free DMEM or RPMI, 
respectively, and were incubated at 37°C for 3 hours. After the addition of 
CellTiter-Blue solution (Promega, Duebendorf, Switzerland), cells were 
incubated for 4 hours and fluorescence was recorded at 560/ 590 nm 
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according to manufacturer’s protocol. Data represent means ± SD from 
technical replicates. 
 
Cell Proliferation Assay 
Proliferation rates of the HC11 and COS-7 cells were determined using the 
chemiluminescent Cell Proliferation ELISA, BrdU incorporation assay 
(Roche). HC11 and COS-7 cells were plated in triplicates on black, clear 
bottom, 96-well microtiter plates (PerkinElmer, Schwerzenbach, Switzerland) 
in 3% FCS/RPMI at 5×103 cells/well and 3×103 cells/well, respectively, were 
incubated at 37°C and allowed to proliferate for 24, 48 and 72 hours at which 
time points cells were labeled with BrdU for 2 h. BrdU incorporation was 
determined according to the manufacturer’s protocol using a Luminometer 
Mithras LB940 (Berthold Technologies, Regensdorf, Switzerland). Data 
represent means ± SD from technical replicates. 
 
Boyden Chamber Cell Migration Assay 
Directed migration of COS-7 cells was analyzed using transwell 
polycarbonate membrane inserts (6.5 mm; Corning, Amsterdam, The 
Netherlands) with 8 µm pore. 3×104 cells were plated in the top insert 
chamber in 100 µl serum-free DMEM. The lower chamber was filled with 600 
µl 10% FCS/DMEM. Cells were incubated at 37°C and were allowed to 
migrate across the transwell filters for 16 hours. Migrated cells were fixed and 
stained with crystal violet. 3 Images/ insert were acquired on a Nikon Eclipse 
E600 using 4X magnification and a color CCD camera. Migration was 
quantified by measuring the area covered by migrated cells using the Fiji 
distribution of ImageJ. Data represent means ± SD from technical replicates. 
 
Wound Healing Scratch Assay 
2×106 COS-7 cells and 3×106 HC11 cells were plated on 60 mm plates in 
DMEM and RPMI medium, respectively, supplemented with 10% FCS, and 
incubated at 37°C overnight. A single uniform scratch was made on the 
confluent monolayer of cells as described by Liang et al., 2007.  The wells 
were then washed with RPMI/ DMEM media to remove the detached cells. 
Before taking the images, fresh media were added to the culture. The first 
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picture was taken at time point “0”.  Migrating cells were allowed to infiltrate 
the scratch for 12 hours and an image at the same position was recorded 
once again. For image acquisition a Nikon light microscope was used.  
 
Wnt3A treatment 
L Wnt-3A (ATCC® CRL-2647TM) cells express and secrete a non-tagged form 
Wnt3A protein (Shibamoto et al., 1998, Willert et al., 2003). L Wnt-3A cells 
and the control parental cell line (ATCC® CRL-2648 TM) were cultured in 10% 
FCS/ DMEM and conditioned media were collected according to the 
manufacturer’s protocol. Parental HC11, 67NR, 168FARN, 4T07 and 4T1 
cells were incubated for 12 and 24 hours in L-Wnt3a or L-control conditioned 
media diluted with fresh 10% FCS/ DMEM (1:2). Following Wnt3A treatment, 
total RNA was isolated and mRNA levels were analyzed as described in 
“Quantitative Reverse-Transcriptase PCR”. 
 
Irradiation of mice 
5- to 7-week old BALB/c female mice (Charles River Laboratories) were used 
as host animals to graft tumors. Primary tumors were initiated by the injection 
of 4T1 cells (5x104 cells/mouse, in 50 µl of 1:5 mixture of Matrigel (BD 
Biosciences) and PBS) into the right fourth mammary gland. Before injection, 
the mammary gland was locally irradiated with a single 20 Gy dose using an 
X-ray unit (Philips, RT 250, Germany), operated at a 125 kV, 20 mA, with a 2-
mm Al filter (Monnier et al., 2008; Kuonen et al., 2012). Mice were sacrificed 
18 days after tumor cell injection. Tissue samples (tumors and mammary 
glands) were collected, flash-frozen in precooled tubes and homogenized in 
RLT buffer using a Dispomix Drive (5x the “40sec grad” profile; Medic Tools). 
Total RNA from tissue homogenates was isolated and mRNA levels were 
analyzed as described in “Quantitative Reverse-Transcriptase PCR”. 
Irradiation, homogenization and RNA isolation procedures are the same for 
the normal mammary glands without the injection of 4T1 tumor cells. All 
animal experiments were approved by the Swiss veterinary authorities. 
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Quantitative Reverse-Transcriptase PCR 
Using the RNeasy Mini Kit (Qiagen), total RNA was isolated from parental 
67NR, 168FARN, 4T07 and 4T1 cells after overnight incubation in 0.03% 
FCS/DMEM. RNA was reverse transcribed and relative WISP1 mRNA levels 
were detected as described in Asparuhova et al., (2011) and Gurbuz et al., 
(2014). Relative WISP1 mRNA levels normalized to Gapdh, were measured 
using Platinum® SYBR® Green qPCR SuperMix-UDG with ROX (Invitrogen). 
WISP1 primers can be found in Gurbuz et al., (2014) (Chapter 2.1.1, 
Additional file: Table S4). Real-time PCR was performed in StepOnePlus 
Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland) using a 
standard cycling profile. All samples were run in duplicate. Endogenous 
WISP1 mRNA expression levels and WISP1 mRNA expression levels upon 
Wnt3a stimulation were analyzed by ΔΔCt method (Livak et al., 2001) that 
included an additional normalization to a control cell line. RNA from pre-
irradiated and normal tumor stroma was analyzed by the ΔCt method 
(Schmittgen et al., 2008). Data represent means ± SD from technical 
replicates. 
 
Protein analyses by Immunoblotting  
After 24 hours of incubation in 0.03% FCS/media, whole-cell extracts were 
prepared by lysis in RIPA buffer and immunoblotting was performed as 
described previously (Maier et al., 2008). HC11 cells were starved in media 
without EGF. Secreted WISP1 protein was detected in cell culture medium. 
Samples were run on 7.5%-12.5% SDS–PAGE and transferred to 
nitrocellulose membrane. Ponceau S (0.1%) staining of the membranes was 
used to visualize the BSA from the medium as loading control. Blots were 
incubated with the following antibodies: anti-WISP1 (diluted in 5% 
milkpowder/ TBS-T, SAB-SY6205 and SAB-SY6206 rabbit polyclonal, 
Eurogentec), anti-myc (diluted 1:100 in 5% milkpowder/ TBS-T, mouse 
monoclonal antibody, Clone: 9E10), anti-Wnt3a (diluted 1:1000 in 5% BSA/ 
TBS-T, C64F2, Rabbit mAb, Cell Signaling), anti-Vcl (diluted 1:1000 in 5% 
milkpowder/ TBS-T, clone hVIN-1, Sigma). Cell lysates of COS-7 cells 
transiently transfected with WISP1 were blotted and probed with the 
polyclonal anti-WISP1 antibody. Proteins were visualized using the primary 
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antibodies listed above followed by horseradish peroxidase-conjugated 
secondary antibodies (1:10,000; MP Biomedicals, France) for detection with 
the ECL Western blotting System (Amersham, Switzerland), and exposed to 
Kodak X-ray film.  
 
Immunofluorescence 
Stable HEKEBNA-WISP1-HIS (5x105 cells), COS-7-WISP1-HIS (3x105 cells), 
HC11-WISP1 (3x105 cells) and 4T1-WISP1 (4x105 cells) cells were plated on 
35×10 mm cell culture dishes with 4 inner rings (Greiner Bio-One GmbH, 
Germany) in 10% FCS supplemented RPMI/ DMEM media. After overnight 
incubation at 37°C, cells were fixed with Zinc Formal-Fixx™ (Thermo Fisher 
Scientific) for 30 minutes, permeabilized with 0.1% Triton X-100 (Fluka, 
Sigma-Aldrich) for 5 minutes and blocked with 3% BSA-PBS for 15 minutes. 
Cells were labeled at room temperature with anti-myc mouse monoclonal 
antibody (diluted 1:20 in blocking solution, Clone: 9E10) for 90 minutes and 
then incubated with Alexa488- or Alexa568-labeled secondary antibodies 
(diluted 1:1000 in blocking solution) for 60 minutes. Cells were mounted in 
Prolong Gold antifade reagent (Invitrogen, Switzerland). Images were taken 
on a Zeiss-Axioscope fluorescent microscope equipped with a 40X objective 
and Hamamatsu ORCA-ER camera. 67NR cells transiently transfected with 
WISP1 (MR205645, Wisp1 (NM_018865) Mouse cDNA ORF Clone, OriGene, 
Rockville, MD, USA) were probed with anti-WISP1 antibody (SY6206 rabbit 
polyclonal, Eurogentec). 24 hours following transfection, 67NR cells were 
fixed and stained as described above.  
 
Deglycosylation with PNGase F 
Total cell lysates and cell culture medium samples of COS-7 cells transiently 
transfected with WISP1 (MR205645, Wisp1 (NM_018865) Mouse cDNA ORF 
Clone, OriGene, Rockville, MD, USA) were treated with Peptide-N-
Glycosidase F (PNGase F, P0704 and P0705, New England Biolabs) 
according to the manufacturer’s protocol. RNase B (P7817S, New England 
Biolabs) was used as a positive control for PNGase F endoglycosidase 
treatment. RNase B is a high mannose glycoprotein that possesses one 
single N-linked glycosylation site  (Plummer and Hirs, 1964). After the SDS-
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PAGE, half of the gel containing RNase B samples was stained with 
InstantBlueTM (Coomassie Blue® based stain, Expedeon). For the other half, 
immunoblotting was performed as described. 
 
Protein concentration by TCA precipitation 
To precipitate proteins within the HEKEBNA-293-WISP1-HIS cell culture 
medium, trichloric acid (TCA) was added to the supernatant sample (Final 
concentration: 10%). The supernatant-TCA mix was vortexed for 10 seconds 
and centrigufed at 4°C at 12000 rpm for 10 minutes. The supernatant was 
removed and 800 µl Aceton (pre-cooled at -20°C) was added. The sample 
was centrifuged at 4°C at 12000 rpm for 5 minutes. The supernatant was 
removed and the pellet was air-dried at room temperature for 60 minutes. 
Finally the pellet was dissolved in sample buffer for SDS-PAGE and 
immunoblotting was performed as described.  
 
Mass Spectrometry Analysis 
To identify the additional proteins that are recognized by our WISP1 
antibodies (SAB-SY6205 and SAB-SY6206 rabbit polyclonal, Eurogentec) 
Mass Spectrometry Analysis was performed. Proteins that were eluted as 
described in “Protein purification from mammalian cells and subsequent 
polyclonal antibody production” were separated via SDS-PAGE. Protein 
bands were excised, washed with 25 mM NH4HCO3 and acetonitrile. Samples 
were reduced with tris(2-carboxyethyl)phosphine (TCEP), alkylated with 
Iodoacetamide and digested with Trypsin overnight at 37 ̊C. Samples were 
acidified with 1 µl 20% Trifluoroacetic acid (TFA) and sonicated for 5 minutes. 
Peptides were analyzed by liquid chromatography mass spectrometry (LTQ 
Orbitrap Velos, Thermo Fisher Scientific). The results were analyzed with 
Scaffold 3.0 (Proteome Software, Portland, Oregon, USA).  
 
Prediction Tools and Bioinformatics Analyses 
Using the Oncomine database (www.oncomine.org) WISP1 expression levels 
in Brain and Central Nervous System Cancer, Breast Cancer, Colorectal 
Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Pancreatic 
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Cancer and Sarcoma were compared to control samples (Cancer vs. Normal 
differential analysis) according to Human Genome U133 Affymetrix Array data 
(Affymetrix Probe ID: 206796_at). Results are represented with a box plot. 
The thick line represents the median value. Minimal and maximal values are 
individually plotted as small dots. Student's t-test was performed by Oncomine 
to generate p-values. 
 
Using NetNGlyc 1.0 Server (Gupta et al., 2004, 
http://www.cbs.dtu.dk/services/NetNGlyc/) potential N-Glycosylation residues 
of WISP1 protein were determined. The server predicts N-Glycosylation sites 
in human proteins. The graph shows predicted N-glyc sites across the protein 
chain. X-axis represents protein length from N- to C-terminal. A position with a 
potential (vertical lines) crossing the threshold (horizontal line at 0.5) is 
predicted to be glycosylated. 
 
Statistical analysis 
Differences between 2 groups were assessed by Student’s t-test. All analyses 
were carried out using GraphPad InStat 3.05 software (GraphPad, San Diego, 
CA, USA). Values of P < 0.05 were considered significant. 
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4.2 Supplementary Figures 
 
 
	
  	
  
Supplementary Figure 1: The Universal Protein Resource (UniProt) protein alignment of the 
six human CCN proteins. Signal peptides at the N-terminus, disulfide bonds and potential 
glycosylation residues were annotated. The tree based on genetic distance is shown. 	
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Supplementary Figure 2: Vectors that were used for WISP1 gene transfer. A) pCMV6-
WISP1 (MR205645, WISP1 mouse cDNA ORF Clone, C-terminal Myc and DDK Tagged) was 
used for transient transfections. B) Bicistronic pQCXIX Retroviral Vector. WISP1 gene and 
the selection marker neomycin (Neo) were cloned in the multiple cloning site I (MCS I) and 
multiple cloning site II (MCS II) of the vector, respectively. pQC-Neo-WISP1 was used for 
stable transfections of HC11 and 4T1 mouse mammary epithelial cells. C) pCEP-pu 
expression vector. HIS-tag was added to WISP1 gene and WISP1-HIS was cloned in the 
pCEP-pu vector. pCEP-Pu-WISP1-HIS was used for stable transfection of COS-7 and EBNA-
293 cells and subsequent protein purification from the cell culture medium.  
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